{"da7c1c4ea5531ba3741326c72dff05506e21140f": [["instead are using face coverings improvised from common fabrics.", [["face coverings", "TREATMENT", 18, 32]]], ["Our goal was to determine 23 what fabrics would be most effective in both practices.25Methods and findings 26 We examined the hydrophobicity of fabrics (silk, cotton, polyester), as measured by their 27 resistance to the penetration of small and aerosolized water droplets, an important transmission 28 avenue for the virus causing COVID-19.", [["silk, cotton, polyester", "CHEMICAL", 153, 176], ["silk", "TISSUE", 153, 157], ["fabrics (silk, cotton, polyester", "TREATMENT", 144, 176], ["small and aerosolized water droplets", "TREATMENT", 236, 272], ["the virus", "PROBLEM", 314, 323], ["COVID", "TEST", 332, 337], ["small", "OBSERVATION_MODIFIER", 236, 241]]], ["We also examined the breathability of these fabrics and 29 their ability to maintain hydrophobicity despite undergoing repeated cleaning.", [["these fabrics", "TREATMENT", 38, 51], ["repeated cleaning", "TREATMENT", 119, 136]]], ["Tests were done 30 when fabrics were fashioned as an overlaying barrier and also when constructed as do-it-yourself 31 face coverings.", [["Tests", "TEST", 0, 5], ["an overlaying barrier", "TREATMENT", 50, 71]]], ["As a protective barrier and face covering, silk is more effective at impeding the 32 penetration and absorption of droplets due to its greater hydrophobicity relative to other tested 33 fabrics.", [["a protective barrier and face covering, silk", "TREATMENT", 3, 47], ["absorption of droplets", "TREATMENT", 101, 123], ["its greater hydrophobicity", "PROBLEM", 131, 157], ["more effective", "OBSERVATION_MODIFIER", 51, 65]]], ["Silk face coverings repelled droplets as well as masks, but unlike masks they are 34 hydrophobic and can be readily sterilized for immediate reuse.36All rights reserved.", [["face", "ANATOMY", 5, 9], ["Silk face coverings repelled droplets", "TREATMENT", 0, 37], ["repelled droplets", "OBSERVATION", 20, 37]]], ["No reuse allowed without permission.36(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.36The copyright holder for this preprint this version posted June 29, 2020. shortages of these items will likely continue in many locations for the foreseeable future.", [["med", "ANATOMY", 117, 120]]], ["45 Although respirators and masks used by health care providers (HCP) and essential workers (EW) 46 form part of the critical armament against COVID-19, a significant drawback of PPE are that 47 they are purposed for only single use.", [["COVID", "TEST", 143, 148]]], ["Sterilization of PPE, especially respirators, has been 48 implemented to enable their continued and repeated use, but this approach reduces the ability of 49 respirators to effectively block particles, can induce damage, or may render the equipment unsafe 50 for further usage [1] .", [["Sterilization of PPE", "TREATMENT", 0, 20]]], ["51 In some cases, HCPs and EWs may only have a single respirator provided to them at their 52 workplace and must reuse them indefinitely under hazardous work conditions.", [["a single respirator", "TREATMENT", 45, 64]]], ["To prolong the 53 life of respirators, many HCPs have adopted the clinical practice of wearing multiple pieces of 54 PPE simultaneously, e.g., a mask on top of a respirator (Fig 1A) [2] [3] [4] .", [["a mask", "TREATMENT", 143, 149], ["a respirator (Fig 1A)", "TREATMENT", 160, 181]]], ["This strategy is 55 unsustainable as increased thickness hampers breathing [3] and increases moisture near the 56 wearer's face, thus becoming a conduit for viral transmission [5, 6] .", [["increased thickness hampers breathing", "PROBLEM", 37, 74], ["a conduit", "TREATMENT", 143, 152], ["increased", "OBSERVATION_MODIFIER", 37, 46], ["thickness", "OBSERVATION_MODIFIER", 47, 56], ["conduit", "OBSERVATION", 145, 152]]], ["No reuse allowed without permission.36(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.36The copyright holder for this preprint this version posted June 29, 2020. . https://doi.org/10.1101/2020.06.25.20136424 doi: medRxiv preprint 4 EWs remain vulnerable as they have resorted to using (and reusing) less efficient masks on their 59 own when respirators are unavailable, leaving them at greater risk to viral transmission. to prolong and preserve N95 respirators is to layer a surgical mask over it [4] .", [["medRxiv preprint 4 EWs", "TREATMENT", 300, 322], ["a surgical mask", "TREATMENT", 561, 576], ["med", "ANATOMY", 117, 120], ["viral transmission", "OBSERVATION", 489, 507]]], ["(B) A 64 commercially available, task-specific surgical mask (top) compared to a silk face covering 65 (bottom) made according to design specifications by the Center for Disease Control and 66 Prevention (CDC) [7] .", [["specific surgical mask", "TREATMENT", 38, 60], ["a silk face", "TREATMENT", 79, 90], ["Disease Control", "TREATMENT", 170, 185]]], ["68 69 PPE shortages are now affecting the general population, especially employees instructed to 70 wear masks in the workplace as well as people in public places where mask wearing is 71 mandatory or strongly recommended as part of public health policy [7, 8] .", [["people", "ORGANISM", 139, 145], ["people", "SPECIES", 139, 145]]], ["As a result, the 72 majority of the general public has been reduced to using improvised face coverings constructed 73 from commercially available materials ( Fig 1B) [9, 10] .", [["improvised face coverings", "TREATMENT", 77, 102]]], ["Although the primary purpose of face 74 coverings is to minimize potential viral transmission from the wearer to others [11] , they can also 75 provide some protection to the wearer from external sources [12, 13] (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.98Experimental design 99 We tested silk material relative to other commercially available fabrics as a protective barrier 100 layer over existing PPE (Fig 1A) and as a material for the construction of face coverings (Fig 101 1B) .", [["potential viral transmission", "PROBLEM", 65, 93], ["fabrics", "TREATMENT", 438, 445], ["a protective barrier", "TREATMENT", 449, 469], ["med", "ANATOMY", 292, 295]]], ["We evaluated five types of material that consisted of animal-derived silk that was natural 102 and unmanipulated (i.e., cocoon walls of B. mori and H. cecropia) or processed (unwashed and 103 washed 100% mulberry silk from pillowcases), processed plant-derived (100% cotton) and 104 All rights reserved.", [["silk", "TISSUE", 69, 73], ["B. mori", "ORGANISM", 136, 143], ["H. cecropia", "ORGANISM", 148, 159], ["B. mori", "SPECIES", 136, 143], ["H. cecropia", "SPECIES", 148, 159], ["B. mori", "SPECIES", 136, 143], ["H. cecropia", "SPECIES", 148, 159], ["material", "TREATMENT", 27, 35], ["animal-derived silk", "TREATMENT", 54, 73]]], ["No reuse allowed without permission.98(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.98The copyright holder for this preprint this version posted June 29, 2020. . https://doi.org/10.1101/2020.06.25.20136424 doi: medRxiv preprint 6 synthetic (polyester) fabrics, as well as a water-absorbent material as a positive control (paper 105 towels, see S1 File for material details).", [["polyester", "CHEMICAL", 330, 339], ["medRxiv preprint 6 synthetic (polyester) fabrics", "TREATMENT", 300, 348], ["a water-absorbent material", "TREATMENT", 361, 387], ["a positive control", "TREATMENT", 391, 409], ["med", "ANATOMY", 117, 120]]], ["These processed fabrics (silk, cotton, and polyester) 106 represent commonly available materials that can be readily used for making protective layers and 107 face coverings.", [["silk, cotton, and polyester", "CHEMICAL", 25, 52], ["silk", "TISSUE", 25, 29], ["layers", "TISSUE", 144, 150], ["These processed fabrics (silk, cotton, and polyester)", "TREATMENT", 0, 53], ["fabrics", "OBSERVATION_MODIFIER", 16, 23]]], ["For processed silk, we tested both washed and unwashed silk to examine if the 108 material properties of silk might be altered by standard cleaning techniques (i.e., washing).", [["processed silk", "TREATMENT", 4, 18], ["unwashed silk", "TREATMENT", 46, 59], ["the 108 material properties of silk", "TREATMENT", 74, 109], ["standard cleaning techniques", "TREATMENT", 130, 158]]], ["109 We compared the different fabric groups in their level of hydrophobicity, functionally 110 characterized by their ability to block either water or aerosolized droplets (from spray), vehicles 111 for the transmission of the virus underlying COVID-19 [30].", [["aerosolized droplets", "TREATMENT", 151, 171], ["vehicles", "TREATMENT", 186, 194], ["the virus underlying COVID", "TEST", 223, 249]]], ["Greater hydrophobicity was defined 112 as the starting contact angles of droplets being greater than 90\u00b0, which produces increased 113 resistance to the penetration of droplets into the fabric.", [["Greater hydrophobicity", "PROBLEM", 0, 22], ["droplets", "TEST", 73, 81], ["hydrophobicity", "OBSERVATION_MODIFIER", 8, 22], ["increased", "OBSERVATION_MODIFIER", 121, 130], ["113 resistance", "OBSERVATION_MODIFIER", 131, 145], ["fabric", "OBSERVATION_MODIFIER", 186, 192]]], ["We assessed hydrophobicity by first 114 measuring the contact angle behavior of an individual water droplet (5 \u00b5L and 2 \u00b5L volumes) 115 deposited onto the surface of these materials using the sessile drop technique.", [["surface", "ANATOMY", 155, 162], ["hydrophobicity", "TEST", 12, 26], ["an individual water droplet", "TREATMENT", 80, 107], ["the sessile drop technique", "TREATMENT", 188, 214]]], ["In these tests, 116 greater contact angles that are more consistent over time indicate greater hydrophobicity.", [["these tests", "TEST", 3, 14], ["greater hydrophobicity", "PROBLEM", 87, 109], ["greater", "OBSERVATION_MODIFIER", 87, 94], ["hydrophobicity", "OBSERVATION", 95, 109]]], ["We 117 also measured the saturation propensity of a droplet (2 \u00b5L) and the rate of gas exchange over a 118 24-hour period through the material to examine the ability of water (liquid and vapor) to 119 penetrate through the material.", [["water", "SIMPLE_CHEMICAL", 169, 174], ["water (liquid and vapor)", "TREATMENT", 169, 193]]], ["Gas exchange rates are a measure of porosity and therefore 120 breathability.", [["Gas", "SIMPLE_CHEMICAL", 0, 3], ["Gas exchange rates", "TEST", 0, 18]]], ["We also compared the performance of single and multi-layered silk in saturation 121 trials.", [["single and multi-layered silk in saturation", "TREATMENT", 36, 79]]], ["Finally, we compared the different fabric types and commercially available surgical 122 masks, in terms of penetration of aerosolized droplets delivered as spray through the material, via 123 a modified custom apparatus [31] .", [["surgical 122 masks", "TREATMENT", 75, 93], ["aerosolized droplets", "TREATMENT", 122, 142]]], ["We also tested vertical aerosolized spray after sterilization 124 where face coverings were sterilized a total of five times using a dry-heat oven at 70 \u00b0C. In all 125 experiments, we tested three different sources for each material type and performed three 126 technical replicates for each source of fabric.", [["vertical aerosolized spray", "TREATMENT", 15, 41], ["sterilization", "TREATMENT", 48, 61], ["a dry-heat oven", "TREATMENT", 131, 146], ["fabric", "PROBLEM", 302, 308]]], ["Thickness measurements were made in three 127 All rights reserved.", [["Thickness measurements", "TEST", 0, 22]]], ["No reuse allowed without permission.98(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.98The copyright holder for this preprint this version posted June 29, 2020. . https://doi.org/10.1101/2020.06.25.20136424 doi: medRxiv preprint separate locations on the material and fabric then averaged.", [["medRxiv", "TREATMENT", 300, 307], ["med", "ANATOMY", 117, 120]]], ["More details on these methods, tests, 128 and sterilization are found in S1 File. with material thickness as a covariate.", [["material", "TISSUE", 87, 95], ["these methods", "TEST", 16, 29], ["tests", "TEST", 31, 36], ["sterilization", "TREATMENT", 46, 59], ["material thickness", "TREATMENT", 87, 105], ["material thickness", "OBSERVATION_MODIFIER", 87, 105]]], ["Gas exchange data were first log10-transformed to meet 141 assumptions of normality, and then compared among material types using a one-way ANOVA.142Comparisons of the percentage of samples that were penetrated by a 2 \u00b5L water droplet for 143 either single or multilayered silk fabric layers were analyzed using a Fisher's Exact omnibus test, 144 which was then followed by pairwise Fisher's Exact tests with Bonferroni correction (\u03b1 = 0.016).145Relative to when no face covering was present over a testing surface, we compared the capability 146 of face coverings (cotton, silk, and polyester) and surgical masks to repel aerosolized droplets 147 (i.e., resist penetration and saturation by aerosol droplets delivered via spray) using a one-way (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.152Testing the performance of material for use as protective barriers and face coverings 153 We found that material groups differed significantly in starting contact angles for both 154 droplet volumes tested (5 \u00b5L -ANCOVA: F6,55=16.88, P<0.001; \u03b7 2 =0.62, \u03b7p 2 =0.64; 2 \u00b5L -155 ANCOVA: F6,55=20.36, P<0.001; \u03b7 2 =0.68, \u03b7p 2 =0.69).", [["samples", "ANATOMY", 182, 189], ["surface", "ANATOMY", 507, 514], ["face", "ANATOMY", 550, 554], ["cotton", "ORGANISM_SUBDIVISION", 566, 572], ["silk", "TISSUE", 574, 578], ["Gas exchange data", "TEST", 0, 17], ["a 2 \u00b5L water droplet", "TREATMENT", 214, 234], ["single or multilayered silk fabric layers", "TREATMENT", 250, 291], ["a Fisher's Exact omnibus test", "TEST", 312, 341], ["Bonferroni correction", "TREATMENT", 409, 430], ["face coverings (cotton, silk, and polyester)", "TREATMENT", 550, 594], ["surgical masks to repel aerosolized droplets", "TREATMENT", 599, 643], ["aerosol droplets", "TREATMENT", 692, 708], ["protective barriers and face coverings", "TREATMENT", 931, 969], ["droplet volumes", "TEST", 1067, 1082], ["ANCOVA", "TEST", 1097, 1103], ["P", "TEST", 1118, 1119], ["\u03b7p", "TEST", 1138, 1140], ["\u00b5L", "TEST", 1152, 1154], ["ANCOVA", "TEST", 1160, 1166], ["P", "TEST", 1181, 1182], ["\u03b7", "TEST", 1190, 1191], ["\u03b7p", "TEST", 1201, 1203], ["med", "ANATOMY", 825, 828]]], ["In all trials, silk-based materials (B. mori 156 and H. cecropia cocoons, unwashed and washed silk) were found to be hydrophobic, as they had 157 starting contact angles approximately or greater than 90\u00b0 (S1 Table) .", [["B. mori 156", "ORGANISM", 37, 48], ["H. cecropia cocoons", "ORGANISM", 53, 72], ["B. mori", "SPECIES", 37, 44], ["H. cecropia", "SPECIES", 53, 64], ["B. mori", "SPECIES", 37, 44], ["H. cecropia cocoons", "SPECIES", 53, 72], ["silk-based materials", "TREATMENT", 15, 35], ["H. cecropia cocoons", "TREATMENT", 53, 72]]], ["In contrast, cotton, 158 polyester, and paper towel materials were classified as hydrophilic as starting angles were far 159 below 90\u00b0 or had immediate droplet absorption (S1 Table) .", [["cotton, 158 polyester", "CHEMICAL", 13, 34], ["paper towel materials", "TREATMENT", 40, 61]]], ["Thickness was significantly related Table) . (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.152The copyright holder for this preprint this version posted June 29, 2020.", [["med", "ANATOMY", 124, 127]]], ["Table) .184The magnitude of change from start to final contact angles was significantly different across Table) .188The saturation propensity of a 2 \u00b5L water droplet significantly differed between material 189 groups (ANCOVA: F6,49=55.875, P<0.001; \u03b7 2 =0.74, \u03b7p 2 =0.87), with cotton and paper towel 190 having the largest droplet spread followed by the remaining groups (Table 1) (Table 1) .188196 All rights reserved.", [["The saturation", "TEST", 116, 130], ["a 2 \u00b5L water droplet", "TREATMENT", 145, 165], ["ANCOVA", "TEST", 218, 224], ["P", "TEST", 240, 241], ["\u03b7p", "TEST", 260, 262], ["cotton", "TREATMENT", 278, 284], ["paper towel", "TEST", 289, 300], ["the largest droplet spread", "PROBLEM", 312, 338], ["largest", "OBSERVATION_MODIFIER", 316, 323]]], ["No reuse allowed without permission.188(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.188The copyright holder for this preprint this version posted June 29, 2020.", [["med", "ANATOMY", 118, 121]]], ["To test the resistance of silk layers, we compared the ability of a 2 \u00b5L water droplet to 208 penetrate single and multiple fabric layers.", [["silk layers", "MULTI-TISSUE_STRUCTURE", 26, 37], ["the resistance of silk layers", "TREATMENT", 8, 37], ["a 2 \u00b5L water droplet", "TREATMENT", 66, 86], ["multiple fabric layers", "TREATMENT", 115, 137], ["multiple", "OBSERVATION_MODIFIER", 115, 123], ["fabric layers", "OBSERVATION", 124, 137]]], ["We found that droplet penetration of silk fabric 209 significantly decreased as the layers of silk increased from a single layer to either double or triple 210 layers (Fisher's Exact, P<0.001), but two and three layers of silk did not differ from each other 211 All rights reserved.", [["silk", "ANATOMY", 94, 98], ["silk fabric 209", "CHEMICAL", 37, 52], ["droplet penetration of silk fabric", "PROBLEM", 14, 48], ["Fisher's Exact", "TEST", 168, 182], ["droplet penetration", "OBSERVATION", 14, 33], ["silk fabric", "OBSERVATION_MODIFIER", 37, 48], ["significantly", "OBSERVATION_MODIFIER", 53, 66], ["decreased", "OBSERVATION_MODIFIER", 67, 76], ["layers", "OBSERVATION_MODIFIER", 84, 90], ["silk", "OBSERVATION_MODIFIER", 94, 98], ["increased", "OBSERVATION_MODIFIER", 99, 108]]], ["No reuse allowed without permission.188(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.188The copyright holder for this preprint this version posted June 29, 2020. . https://doi.org/10.1101/2020.06.25.20136424 doi: medRxiv preprint (S3 Table) .", [["med", "ANATOMY", 118, 121]]], ["As the public typically wears face coverings with one or two layers, we compared the and standard PPE such as surgical masks.", [["surgical masks", "TREATMENT", 110, 124], ["surgical masks", "OBSERVATION", 110, 124]]], ["Our results demonstrate that the greater 234 All rights reserved.", [["greater", "OBSERVATION_MODIFIER", 33, 40]]], ["No reuse allowed without permission.188(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["med", "ANATOMY", 118, 121]]], ["Silk performs similarly to surgical masks when layered over respirators, as they would occur 238 in clinical settings (Fig 1A) , yet has the added advantages of greater hydrophobicity and the 239 ability to be easily cleaned through washing for multiple uses.", [["surgical masks", "TREATMENT", 27, 41], ["greater hydrophobicity", "PROBLEM", 161, 183]]], ["Recent work has also aimed at (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["med", "ANATOMY", 109, 112]]], ["Currently, public health recommendations focus on cotton material for face coverings [14] .", [["cotton material", "TREATMENT", 50, 65]]], ["258 We found that cotton materials are hydrophilic, and readily allow droplets to rapidly penetrate 259 and saturate the fabric like a sponge.", [["cotton materials", "PROBLEM", 18, 34], ["a sponge", "TREATMENT", 133, 141], ["cotton materials", "OBSERVATION", 18, 34], ["hydrophilic", "OBSERVATION_MODIFIER", 39, 50], ["sponge", "OBSERVATION", 135, 141]]], ["Face coverings made out of polyester face these same limitations, as it is 262 hydrophilic like cotton.", [["polyester", "CHEMICAL", 27, 36]]], ["Therefore, cloth and polyester face coverings appear to be more suitable (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.188The copyright holder for this preprint this version posted June 29, 2020. . https://doi.org/10.1101/2020.06.25.20136424 doi: medRxiv preprint 14 non-specialized PPE require copper particles to be infused during the manufacturing process 281 [39], an expensive process that could be circumvented by using natural silk fibers.", [["copper", "CHEMICAL", 384, 390], ["copper", "CHEMICAL", 384, 390], ["copper particles", "SIMPLE_CHEMICAL", 384, 400], ["silk fibers", "MULTI-TISSUE_STRUCTURE", 523, 534], ["cloth and polyester face coverings", "TREATMENT", 11, 45], ["medRxiv preprint", "TREATMENT", 336, 352], ["copper particles", "TREATMENT", 384, 400], ["an expensive process", "TREATMENT", 458, 478], ["natural silk fibers", "TREATMENT", 515, 534], ["med", "ANATOMY", 152, 155]]], ["No reuse allowed without permission.294(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.294The copyright holder for this preprint this version posted June 29, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.294The copyright holder for this preprint this version posted June 29, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.294The copyright holder for this preprint this version posted June 29, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.294The copyright holder for this preprint this version posted June 29, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.294The copyright holder for this preprint this version posted June 29, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.294The copyright holder for this preprint this version posted June 29, 2020.", [["med", "ANATOMY", 118, 121], ["med", "ANATOMY", 330, 333], ["med", "ANATOMY", 542, 545], ["med", "ANATOMY", 754, 757], ["med", "ANATOMY", 966, 969], ["med", "ANATOMY", 1178, 1181]]], ["No reuse allowed without permission.294(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.294The copyright holder for this preprint this version posted June 29, 2020. . https://doi.org/10.1101/2020.06.25.20136424 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.294The copyright holder for this preprint this version posted June 29, 2020. . https://doi.org/10.1101/2020.06.25.20136424 doi: medRxiv preprint 1 S1 File.", [["med", "ANATOMY", 118, 121], ["med", "ANATOMY", 398, 401]]], ["Protocol for experiments.Materials and fabrics testedWe tested five material groups for contact angle, saturation propensity, and gas exchange rates, then tested three fabric groups for droplet penetration of single and multiple layers, and for resistance to aerosolized spray.", [["contact angle", "TEST", 88, 101], ["saturation propensity", "TEST", 103, 124], ["gas exchange rates", "TEST", 130, 148], ["droplet penetration", "PROBLEM", 186, 205], ["aerosolized spray", "TREATMENT", 259, 276], ["multiple", "OBSERVATION_MODIFIER", 220, 228], ["layers", "OBSERVATION_MODIFIER", 229, 235]]], ["For animal-derived silk that was natural and unmanipulated, we took Bombyx mori cocoon samples from our current laboratory colony (3 rd we tested a 100% cotton handkerchief (thickness: 0.158 \u00b1 0.010 mm), 100% cotton fabric (thickness: 0.199 \u00b1 0.006 mm), and a 100% Egyptian cotton pillowcase (thickness: 0.163 \u00b1 0.005mm).", [["silk", "ANATOMY", 19, 23], ["silk", "TISSUE", 19, 23], ["Bombyx mori", "ORGANISM", 68, 79], ["Bombyx mori", "SPECIES", 68, 79], ["Bombyx mori", "SPECIES", 68, 79], ["animal-derived silk", "TREATMENT", 4, 23], ["thickness", "TEST", 174, 183], ["cotton fabric (thickness", "TEST", 209, 233], ["thickness", "TEST", 293, 302]]], ["Synthetic materials tested included a pillowcase that was a blend of 88% polyester -12% nylon (thickness: 0.152 \u00b1 0.002 mm), a 100% polyester pillowcase (thickness: 0.103 \u00b1 0.001 mm), and a 100% polyester drawstring bag (thickness: 0.088 \u00b1 0.005 mm).", [["polyester", "CHEMICAL", 73, 82], ["polyester", "CHEMICAL", 132, 141], ["polyester", "CHEMICAL", 195, 204], ["a 100% polyester pillowcase (", "TREATMENT", 125, 154], ["thickness", "TEST", 154, 163], ["a 100% polyester drawstring bag", "TREATMENT", 188, 219]]], ["The 100%Materials and fabrics testedEgyptian cotton pillowcase, 100% cotton handkerchief, 100% cotton fabric, 100% polyester pillowcase, 88% polyester-12% nylon pillowcase, and 100% polyester drawstring bag were purchased two-years prior from various retailers (Walmart, USA; JoAnn Fabrics, USA).", [["handkerchief", "CHEMICAL", 76, 88], ["polyester pillowcase", "CHEMICAL", 115, 135], ["polyester", "CHEMICAL", 141, 150], ["polyester", "CHEMICAL", 115, 124], ["polyester", "CHEMICAL", 141, 150], ["polyester", "CHEMICAL", 182, 191], ["cotton", "SPECIES", 45, 51], ["cotton", "SPECIES", 45, 51], ["cotton", "SPECIES", 69, 75], ["cotton", "SPECIES", 95, 101], ["The 100%Materials", "TREATMENT", 0, 17], ["fabrics", "TEST", 22, 29], ["100% polyester drawstring bag", "TREATMENT", 177, 206]]], ["Positive All rights reserved.", [["All", "OBSERVATION_MODIFIER", 9, 12], ["rights reserved", "OBSERVATION", 13, 28]]], ["No reuse allowed without permission.Materials and fabrics tested(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Water droplet contact angleContact angle data for 5 \u00b5L and 2 \u00b5L water droplet trials were collected using an experimental setup based on those used in previous work [2] .", [["2 \u00b5L water droplet trials", "TREATMENT", 258, 283], ["an experimental setup", "TREATMENT", 305, 326], ["med", "ANATOMY", 143, 146]]], ["The droplet volumes were based on the range of values previously used to test natural materials and fabrics [3, 4] .", [["The droplet volumes", "TEST", 0, 19], ["droplet volumes", "OBSERVATION", 4, 19]]], ["The contact angle of a water droplet deposited onto the material surface (using the sessile drop technique; see below) was used to determine the hydrophobicity of the test material based on the angle produced by the edge of a water droplet contacting the material surface.", [["surface", "ANATOMY", 264, 271], ["a water droplet", "TREATMENT", 21, 36], ["the sessile drop technique", "TREATMENT", 80, 106], ["a water droplet", "TREATMENT", 224, 239], ["angle", "OBSERVATION_MODIFIER", 12, 17], ["water droplet", "OBSERVATION", 23, 36], ["surface", "OBSERVATION_MODIFIER", 65, 72], ["edge", "OBSERVATION_MODIFIER", 216, 220], ["water droplet", "OBSERVATION", 226, 239], ["material", "OBSERVATION_MODIFIER", 255, 263], ["surface", "OBSERVATION_MODIFIER", 264, 271]]], ["We vertically deposited the water droplet (5 or 2 \u00b5L) onto the fabric piece using a pipette.", [["the water droplet", "TREATMENT", 24, 41], ["the fabric piece", "TREATMENT", 59, 75], ["a pipette", "TREATMENT", 82, 91], ["water droplet", "OBSERVATION", 28, 41]]], ["We avoided any effects of kinetic energy on the contact angle formed by the droplet by ensuring the droplet was in contact with both the pipet tip and the surface of the material swatch prior to final deposition [5] .", [["surface", "ANATOMY", 155, 162], ["surface", "CELLULAR_COMPONENT", 155, 162], ["kinetic energy", "PROBLEM", 26, 40], ["the pipet tip", "TREATMENT", 133, 146]]], ["We used a high-resolution digital camera (Micro 4/3 Lumix SLR, Panasonic Corporation) to capture trial images.", [["a high-resolution digital camera", "TREATMENT", 8, 40], ["capture trial images", "TEST", 89, 109]]], ["During all trials, the camera was kept level with the water droplet and test material.Water droplet contact angleWe performed trials on a plastic platform that was positioned horizontally and leveled using a leveler (Bullseye Surface Level, Empire Level).", [["the camera", "TEST", 19, 29], ["the water droplet", "TREATMENT", 50, 67], ["a plastic platform", "TREATMENT", 136, 154], ["a leveler (Bullseye Surface Level", "TREATMENT", 206, 239]]], ["No reuse allowed without permission.Water droplet contact angle(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Water droplet contact angleThe copyright holder for this preprint this version posted June 29, 2020. . https://doi.org/10.1101/2020.06.25.20136424 doi: medRxiv preprint 3 angle measurements (mean angle of the contact angle of the left and right sides of the droplet as seen in images): the initial contact angle (time = 0 s, the first image that the pipette tip was completely out of frame), the dynamic contact angle (mean contact angle, sampled every five seconds, and averaged at the end of the trial), and the final (defined as the last reliable image in which the contact angle could be determined or at t = 120s).", [["left", "ANATOMY", 428, 432], ["right sides", "ANATOMY", 437, 448], ["the pipette tip", "TREATMENT", 544, 559], ["med", "ANATOMY", 142, 145], ["left", "ANATOMY_MODIFIER", 428, 432], ["right", "ANATOMY_MODIFIER", 437, 442]]], ["We tested the contact angle of a 5 \u00b5L and 2 \u00b5L water droplets separately.Water droplet contact angleImages were sampled every second for a total duration of two minutes and then uploaded to ImageJ 1.52a (http://rsb.info.nih.gov/ij/) for analysis.", [["a 5 \u00b5L", "TREATMENT", 31, 37], ["2 \u00b5L water droplets", "TREATMENT", 42, 61], ["Water droplet contact angleImages", "TREATMENT", 73, 106], ["ImageJ", "TEST", 190, 196], ["analysis", "TEST", 237, 245]]], ["The two points of contact were then identified as the outer most points at which the droplet touched the material surface.", [["surface", "ANATOMY", 114, 121], ["material surface", "CELLULAR_COMPONENT", 105, 121], ["contact", "OBSERVATION", 18, 25], ["droplet", "OBSERVATION", 85, 92], ["material", "OBSERVATION_MODIFIER", 105, 113], ["surface", "OBSERVATION_MODIFIER", 114, 121]]], ["A straight line was then drawn with the angle tool connecting the two points of contact, parallel to the plane of the material, and the angle line was drawn tangential to the point of contact between the droplet and the material.", [["A straight line", "TREATMENT", 0, 15], ["the angle line", "TREATMENT", 132, 146], ["straight line", "OBSERVATION", 2, 15], ["angle line", "OBSERVATION", 136, 146]]], ["This technique was done for both the right and left side of the droplet and then averaged to obtain the mean contact angle [6] .", [["right", "ANATOMY", 37, 42], ["This technique", "TEST", 0, 14], ["right", "ANATOMY_MODIFIER", 37, 42], ["left", "ANATOMY_MODIFIER", 47, 51]]], ["A contact angle measurement was determined unreliable if either of the two points of contact or the curvature of the droplet could not be determined.Saturation propensity and gas exchangeSaturation propensity was measured as the absorption of a water droplet and was used to test the permeability of the test material.", [["A contact angle measurement", "TEST", 0, 27], ["Saturation propensity", "TEST", 149, 170], ["gas exchangeSaturation propensity", "PROBLEM", 175, 208], ["a water droplet", "TREATMENT", 243, 258], ["the test material", "TEST", 300, 317], ["gas exchangeSaturation", "OBSERVATION", 175, 197]]], ["For each trial, we applied a 2 \u00b5L water droplet and waited 1-minute before taking an image of the material to measure the total area that the water droplet had spread within the material.", [["a 2 \u00b5L water droplet", "TREATMENT", 27, 47], ["the water droplet", "PROBLEM", 138, 155], ["water droplet", "OBSERVATION", 142, 155]]], ["Images were analyzed using ImageJ.", [["Images", "TEST", 0, 6], ["ImageJ", "TEST", 27, 33]]], ["If the water droplet was not absorbed at the end of 1-minute, we measured the area of the water droplet.", [["the water droplet", "PROBLEM", 3, 20], ["the water droplet", "TREATMENT", 86, 103], ["water droplet", "OBSERVATION", 90, 103]]], ["The water droplet All rights reserved.", [["The water droplet", "TREATMENT", 0, 17], ["water droplet", "OBSERVATION", 4, 17]]], ["No reuse allowed without permission.Saturation propensity and gas exchange(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Saturation propensity and gas exchangeThe copyright holder for this preprint this version posted June 29, 2020. . https://doi.org/10.1101/2020.06.25.20136424 doi: medRxiv preprint 4 was applied using a similar technique as above by ensuring the droplet was in contact with the material first before depositing the droplet.Saturation propensity and gas exchangeWe tested the rate of gas exchange for each material by using methods that were modified from previous studies [7, 8] .", [["Saturation propensity", "TEST", 36, 57], ["gas exchange", "TEST", 62, 74], ["Saturation propensity", "TEST", 209, 230], ["gas exchange", "TEST", 235, 247], ["medRxiv preprint 4", "TREATMENT", 372, 390], ["a similar technique", "TREATMENT", 409, 428], ["Saturation propensity", "TEST", 531, 552], ["gas exchangeWe", "TEST", 557, 571], ["previous studies", "TEST", 663, 679], ["gas exchange", "OBSERVATION", 62, 74], ["med", "ANATOMY", 153, 156], ["gas exchange", "OBSERVATION", 235, 247]]], ["First, we built an airtight holder for material swatches through which only water vapor was allowed to evaporate.", [["an airtight holder", "TREATMENT", 16, 34], ["material swatches", "TREATMENT", 39, 56], ["water vapor", "TREATMENT", 76, 87], ["airtight", "OBSERVATION", 19, 27]]], ["The apparatus was created from a 0.3 mL micro reaction vessel with a hole in the rubber seal to keep the vessel airtight.", [["vessel", "ANATOMY", 55, 61], ["vessel", "ANATOMY", 105, 111], ["vessel", "MULTI-TISSUE_STRUCTURE", 55, 61], ["vessel", "MULTI-TISSUE_STRUCTURE", 105, 111], ["a 0.3 mL micro reaction vessel", "TREATMENT", 31, 61], ["a hole in the rubber seal", "TREATMENT", 67, 92], ["vessel", "ANATOMY", 55, 61], ["hole", "OBSERVATION_MODIFIER", 69, 73], ["rubber seal", "OBSERVATION", 81, 92], ["vessel", "ANATOMY", 105, 111], ["airtight", "OBSERVATION", 112, 120]]], ["Each micro reaction vessel was filled with water (300 \u00b5L), covered with the material swatch and airtight cap, and then placed on an electronic balance in the room to obtain the initial weight and to measure the weight change after a 24-hour period.", [["vessel", "ANATOMY", 20, 26], ["vessel", "MULTI-TISSUE_STRUCTURE", 20, 26], ["Each micro reaction vessel", "TREATMENT", 0, 26], ["the material swatch", "TREATMENT", 72, 91], ["airtight cap", "TREATMENT", 96, 108], ["vessel", "ANATOMY", 20, 26], ["airtight cap", "OBSERVATION", 96, 108]]], ["We recorded the ambient temperature and humidity of the room for the duration of these tests to correct for the water vapor transfer rate [9] .Single and multi-layer silk water droplet absorptionWe determined how increasing the number of layers of silk affects the ability of silk to be an effective barrier by comparing the ability of a 2 \u00b5L water droplet to penetrate one, two, and three layers of silk fabric for washed and unwashed silk groups.", [["these tests", "TEST", 81, 92], ["the water vapor transfer rate", "TREATMENT", 108, 137], ["Single and multi-layer silk water droplet absorption", "TREATMENT", 143, 195], ["an effective barrier", "TREATMENT", 287, 307], ["a 2 \u00b5L water droplet", "TREATMENT", 336, 356], ["silk fabric", "TREATMENT", 400, 411], ["unwashed silk groups", "TREATMENT", 427, 447], ["increasing", "OBSERVATION_MODIFIER", 213, 223], ["number", "OBSERVATION_MODIFIER", 228, 234], ["layers", "OBSERVATION_MODIFIER", 238, 244]]], ["For each trial, we placed a 7.62 cm by 12.70 cm notecard on a Styrofoam mannequin head (Fig. S1a) , which covered the nose, mouth, and upper cheek areas (left and right) while the mannequin head was in a horizontal position (Fig. S1b) .", [["head", "ANATOMY", 82, 86], ["nose", "ANATOMY", 118, 122], ["mouth", "ANATOMY", 124, 129], ["upper cheek areas", "ANATOMY", 135, 152], ["left", "ANATOMY", 154, 158], ["head", "ANATOMY", 190, 194], ["nose", "ORGANISM_SUBDIVISION", 118, 122], ["mouth", "ORGANISM_SUBDIVISION", 124, 129], ["upper cheek", "ORGANISM_SUBDIVISION", 135, 146], ["head", "ORGANISM_SUBDIVISION", 190, 194], ["a Styrofoam mannequin head", "TREATMENT", 60, 86], ["head", "ANATOMY", 82, 86], ["nose", "ANATOMY", 118, 122], ["mouth", "ANATOMY", 124, 129], ["upper", "ANATOMY_MODIFIER", 135, 140], ["cheek", "ANATOMY", 141, 146], ["left", "ANATOMY_MODIFIER", 154, 158], ["right", "ANATOMY_MODIFIER", 163, 168]]], ["Each trial was completed when the 2 \u00b5L droplet was no longer present on the surface of the silk, either through absorption or evaporation.", [["surface", "ANATOMY", 76, 83], ["silk", "ANATOMY", 91, 95], ["silk", "TISSUE", 91, 95], ["the 2 \u00b5L droplet", "TREATMENT", 30, 46], ["no longer", "UNCERTAINTY", 51, 60]]], ["Images were scanned using a flatbed scanner (Canon MG2220, Canon, Inc.), then uploaded and processed in ImageJ v1.52a.", [["Images", "TEST", 0, 6]]], ["Blank index cards (Walmart Inc., AR, USA) were used to identify possible potential discoloration in the card from the manufacturing process that would create a false positive detection during All rights reserved.", [["potential discoloration in the card", "PROBLEM", 73, 108], ["a false positive detection", "PROBLEM", 158, 184], ["discoloration", "OBSERVATION", 83, 96]]], ["No reuse allowed without permission.Single and multi-layer silk water droplet absorption(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Single and multi-layer silk water droplet absorptionThe copyright holder for this preprint this version posted June 29, 2020. . https://doi.org/10.1101/2020.06.25.20136424 doi: medRxiv preprint 5 image analysis.", [["Single and multi-layer silk water droplet absorption", "TREATMENT", 36, 88], ["Single and multi-layer silk water droplet absorption", "TREATMENT", 223, 275], ["image analysis", "TEST", 419, 433], ["med", "ANATOMY", 167, 170]]], ["These were identified as small dark points on the card that differed from discoloration caused by the droplet.Standardizing aerosolized spray trialsThe velocity of the spray was determined through the relationship of flow rate and velocity using the following equations for flow rate (m 3 /s):Standardizing aerosolized spray trials= where Q is the flow rate (m 3 /s), v is the volume (m 3 ), and t is time (s).", [["small dark points on the card", "PROBLEM", 25, 54], ["discoloration", "PROBLEM", 74, 87], ["Standardizing aerosolized spray trials", "TREATMENT", 110, 148], ["the spray", "TREATMENT", 164, 173], ["flow rate", "TEST", 217, 226], ["velocity", "TEST", 231, 239], ["flow rate", "TEST", 274, 283], ["Standardizing aerosolized spray trials", "TREATMENT", 293, 331], ["the flow rate", "TEST", 344, 357], ["small", "OBSERVATION_MODIFIER", 25, 30], ["dark points", "OBSERVATION", 31, 42], ["discoloration", "OBSERVATION", 74, 87], ["velocity", "OBSERVATION_MODIFIER", 152, 160], ["flow rate", "OBSERVATION", 217, 226]]], ["The relationship between flow rate and velocity is as follows:Standardizing aerosolized spray trials= where Q is flow rate (m 3 /s), A is the cross-sectional area of the cylinder (m 2 ), and V is the velocity (m/s).", [["flow rate", "TEST", 25, 34], ["Standardizing aerosolized spray trials", "TREATMENT", 62, 100], ["flow rate", "TEST", 113, 122], ["flow rate", "OBSERVATION", 25, 34]]], ["We solved for velocity by first calculating the flow rate (Q) from equation (1) and then rearranging equation (2) .", [["velocity", "TEST", 14, 22], ["the flow rate", "TEST", 44, 57]]], ["We recorded each spray using a camera (Logitech HD Pro C920) and weighed the apparatus before and after each spray.", [["a camera (Logitech HD Pro C920", "TREATMENT", 29, 59]]], ["The aerosolized spray had an average velocity of 0.88 \u00b1 0.04 m/s with each spray containing 0.125 \u00b1 0.05 mL of liquid.Standardizing aerosolized spray trialsAlthough a real human cough has an extreme amount of variability in droplet size, cough plume, and other characteristics [10] , our device based on a similar experimental design [11] represents an extreme case in which a patient openly coughs in close proximity without any protective barrier.Single and multilayer barrier aerosolized spray test(1)Single and multilayer barrier aerosolized spray test(2) All rights reserved.", [["cough", "DISEASE", 178, 183], ["cough", "DISEASE", 238, 243], ["coughs", "DISEASE", 392, 398], ["human", "ORGANISM", 172, 177], ["patient", "ORGANISM", 377, 384], ["human", "SPECIES", 172, 177], ["patient", "SPECIES", 377, 384], ["human", "SPECIES", 172, 177], ["The aerosolized spray", "TREATMENT", 0, 21], ["an average velocity", "TEST", 26, 45], ["Standardizing aerosolized spray trials", "TREATMENT", 118, 156], ["a real human cough", "PROBLEM", 165, 183], ["variability in droplet size", "PROBLEM", 209, 236], ["cough plume", "PROBLEM", 238, 249], ["our device", "TREATMENT", 284, 294], ["Single and multilayer barrier aerosolized spray test", "TREATMENT", 449, 501], ["Single and multilayer barrier aerosolized spray test", "TREATMENT", 504, 556], ["average", "OBSERVATION_MODIFIER", 29, 36], ["velocity", "OBSERVATION_MODIFIER", 37, 45], ["extreme", "OBSERVATION_MODIFIER", 191, 198], ["amount", "OBSERVATION_MODIFIER", 199, 205], ["variability", "OBSERVATION_MODIFIER", 209, 220], ["droplet", "OBSERVATION_MODIFIER", 224, 231], ["size", "OBSERVATION_MODIFIER", 232, 236], ["cough plume", "OBSERVATION", 238, 249]]], ["No reuse allowed without permission.Single and multilayer barrier aerosolized spray test(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Single and multilayer barrier aerosolized spray testThe copyright holder for this preprint this version posted June 29, 2020. . https://doi.org/10.1101/2020.06.25.20136424 doi: medRxiv preprintSingle and multilayer barrier aerosolized spray testWe compared 100% cotton, polyester, and 100% silk (washed and unwashed) as a single layer and double layer in the aerosolized spray test.", [["Single and multilayer barrier aerosolized spray test", "TREATMENT", 36, 88], ["Single and multilayer barrier aerosolized spray test", "TREATMENT", 223, 275], ["medRxiv preprintSingle", "TREATMENT", 400, 422], ["multilayer barrier aerosolized spray testWe", "TREATMENT", 427, 470], ["polyester", "TREATMENT", 493, 502], ["a single layer and double layer in the aerosolized spray test", "TREATMENT", 543, 604], ["med", "ANATOMY", 167, 170]]], ["We modified an aerosol can with a standard valve, and added 150 ml of black-dyed water (10ml black dye, 140ml water; McCormick, MD, USA).", [["a standard valve", "TREATMENT", 32, 48], ["black-dyed water", "TREATMENT", 70, 86]]], ["Prior to each trial, the aerosol can was filled to 82 kPa with an air pump and checked using a tire-pressure gauge.", [["the aerosol", "TREATMENT", 21, 32], ["an air pump", "TREATMENT", 63, 74], ["a tire-pressure gauge", "TREATMENT", 93, 114], ["air pump", "OBSERVATION", 66, 74]]], ["The Styrofoam mannequin head had a piece of fabric on top of a notecard pinned to the face (Fig. S1a) , and which was placed 0.66m [10] from the aerosol can ( Fig. S2) .", [["head", "ANATOMY", 24, 28], ["face", "ANATOMY", 86, 90], ["head", "ORGANISM_SUBDIVISION", 24, 28], ["S2", "PROTEIN", 164, 166], ["The Styrofoam mannequin head", "TREATMENT", 0, 28], ["face", "ANATOMY", 86, 90]]], ["A control group (no mask) was sprayed to provide a baseline of discoloration for comparison.", [["A control group (no mask", "TREATMENT", 0, 24], ["discoloration", "PROBLEM", 63, 76], ["discoloration", "OBSERVATION", 63, 76]]], ["The aerosolized droplets were of a random distribution in size with the speed and total volume consistent across trials.Face covering and mask aerosolized spray testFace coverings were made according to the CDC guidelines for sewn pleated face coverings [12] , and were made with a single material that consisted of either polyester, cotton, or silk (see above).", [["polyester", "CHEMICAL", 323, 332], ["silk", "TISSUE", 345, 349], ["The aerosolized droplets", "PROBLEM", 0, 24], ["total volume", "TREATMENT", 82, 94], ["mask aerosolized spray test", "TREATMENT", 138, 165], ["sewn pleated face coverings", "TREATMENT", 226, 253], ["aerosolized", "OBSERVATION_MODIFIER", 4, 15], ["droplets", "OBSERVATION", 16, 24], ["random", "OBSERVATION_MODIFIER", 35, 41], ["distribution", "OBSERVATION_MODIFIER", 42, 54], ["size", "OBSERVATION_MODIFIER", 58, 62], ["across trials", "OBSERVATION", 106, 119]]], ["We made three face coverings for each material group and included two brands of surgical masks for comparison in the aerosolized spray test.", [["surgical masks", "TREATMENT", 80, 94], ["the aerosolized spray test", "TEST", 113, 139], ["surgical masks", "OBSERVATION", 80, 94]]], ["Initially, these coverings were tested prior to any sterilization and stretching.", [["any sterilization", "TREATMENT", 48, 65], ["stretching", "PROBLEM", 70, 80]]], ["After the initial trials, the coverings were sterilized using dry heat (70 \u00b0C) for 1-hour each and then retested after a single sterilization and after five sterilizations.", [["dry heat", "TREATMENT", 62, 70], ["a single sterilization", "TREATMENT", 119, 141], ["five sterilizations", "TREATMENT", 152, 171]]], ["After each sterilization, face coverings were worn for approximately 5-minutes and stretched (i.e., diagonally, horizontally, and vertically) to simulate wear-and-tear, and the same masks were used across all trials.Face covering and mask aerosolized spray testImages were processed in ImageJ 1.52a.", [["face", "ANATOMY", 26, 30], ["each sterilization", "TREATMENT", 6, 24], ["face coverings", "TREATMENT", 26, 40], ["tear", "PROBLEM", 163, 167], ["the same masks", "TREATMENT", 173, 187], ["mask aerosolized spray", "TREATMENT", 234, 256], ["tear", "OBSERVATION", 163, 167]]], ["The images were converted into 16-bit images to allow grayscale thresholding to isolate and separate pixels darkened by the aerosolizing apparatus.", [["The images", "TEST", 0, 10], ["grayscale thresholding", "TEST", 54, 76]]], ["Using a positive control, the threshold value was determined by incrementally All rights reserved.", [["a positive control", "TREATMENT", 6, 24], ["the threshold value", "TEST", 26, 45]]], ["No reuse allowed without permission.Face covering and mask aerosolized spray test(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Face covering and mask aerosolized spray testThe copyright holder for this preprint this version posted June 29, 2020. . https://doi.org/10.1101/2020.06.25.20136424 doi: medRxiv preprint increasing the value until both visible spots were sufficiently covered and before there was significant threshold identification on either the white of the card or on the background on which the cards were placed.", [["mask aerosolized spray test", "TREATMENT", 54, 81], ["mask aerosolized spray test", "TREATMENT", 234, 261], ["medRxiv", "TREATMENT", 386, 393], ["significant threshold identification", "PROBLEM", 496, 532], ["med", "ANATOMY", 160, 163]]], ["This tool enabled us to exclude any particles that were obviously not droplets from the aerosolizing apparatus and instead resulted from the experimentation itself.", [["any particles", "PROBLEM", 32, 45]]], ["These included (1) holes created by the pins securing the card to the fabric, (2) large shadowed portions of the card created by unintentional bending or creasing of the card during experimentation, and (3) large fabric remnants or other debris found on the card.Face covering and mask aerosolized spray testAfter these areas were excluded, the total sum area of all the threshold particles was calculated.Face covering and mask aerosolized spray testAll rights reserved.", [["(1) holes", "TREATMENT", 15, 24], ["the pins", "TREATMENT", 36, 44], ["unintentional bending", "PROBLEM", 129, 150], ["large fabric remnants", "PROBLEM", 207, 228], ["other debris", "PROBLEM", 232, 244], ["mask aerosolized spray test", "TREATMENT", 281, 308], ["mask aerosolized spray test", "TREATMENT", 424, 451], ["pins", "OBSERVATION", 40, 44], ["large", "OBSERVATION_MODIFIER", 207, 212], ["fabric", "OBSERVATION_MODIFIER", 213, 219], ["remnants", "OBSERVATION", 220, 228], ["debris", "OBSERVATION", 238, 244], ["threshold particles", "OBSERVATION", 371, 390]]], ["No reuse allowed without permission.Face covering and mask aerosolized spray test(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Face covering and mask aerosolized spray testThe copyright holder for this preprint this version posted June 29, 2020.", [["mask aerosolized spray test", "TREATMENT", 54, 81], ["mask aerosolized spray test", "TREATMENT", 234, 261], ["med", "ANATOMY", 160, 163]]]], "PMC7177691": [], "PMC7094671": [["IntroductionAsthma is a chronic, genetically-determined disease, whose prevalence in the pediatric population ranges between 19.0% and 24.3% among brazilian adolescents and schoolchildren, respectively.1 From the physiopathological viewpoint, it is characterized by chronic inflammation with the involvement of several cell types, associated with airway hyperresponsiveness, with episodes of reversible airflow limitation.", [["cell", "ANATOMY", 319, 323], ["airway", "ANATOMY", 347, 353], ["IntroductionAsthma", "DISEASE", 0, 18], ["inflammation", "DISEASE", 274, 286], ["airway hyperresponsiveness", "DISEASE", 347, 373], ["cell", "CELL", 319, 323], ["airway", "MULTI-TISSUE_STRUCTURE", 347, 353], ["adolescents", "SPECIES", 157, 168], ["schoolchildren", "SPECIES", 173, 187], ["disease", "PROBLEM", 56, 63], ["chronic inflammation", "PROBLEM", 266, 286], ["several cell types", "PROBLEM", 311, 329], ["airway hyperresponsiveness", "PROBLEM", 347, 373], ["reversible airflow limitation", "PROBLEM", 392, 421], ["chronic", "OBSERVATION_MODIFIER", 24, 31], ["chronic", "OBSERVATION_MODIFIER", 266, 273], ["inflammation", "OBSERVATION", 274, 286], ["several cell types", "OBSERVATION", 311, 329], ["airway", "ANATOMY", 347, 353], ["hyperresponsiveness", "OBSERVATION", 354, 373], ["reversible", "OBSERVATION_MODIFIER", 392, 402], ["airflow limitation", "OBSERVATION", 403, 421]]], ["It is clinically manifested by recurrent exacerbations, also called \u201casthma attacks\u201d or, more appropriately, acute asthma, characterized by progressive worsening of dyspnea, coughing, wheezing, chest tightness, or a combination of these.2", [["chest", "ANATOMY", 194, 199], ["asthma attacks", "DISEASE", 69, 83], ["asthma", "DISEASE", 115, 121], ["dyspnea", "DISEASE", 165, 172], ["coughing", "DISEASE", 174, 182], ["wheezing", "DISEASE", 184, 192], ["chest tightness", "DISEASE", 194, 209], ["recurrent exacerbations", "PROBLEM", 31, 54], ["asthma attacks", "PROBLEM", 69, 83], ["acute asthma", "PROBLEM", 109, 121], ["dyspnea", "PROBLEM", 165, 172], ["coughing", "PROBLEM", 174, 182], ["wheezing", "PROBLEM", 184, 192], ["chest tightness", "PROBLEM", 194, 209], ["recurrent", "OBSERVATION_MODIFIER", 31, 40], ["exacerbations", "OBSERVATION", 41, 54], ["acute", "OBSERVATION_MODIFIER", 109, 114], ["asthma", "OBSERVATION", 115, 121], ["progressive", "OBSERVATION_MODIFIER", 140, 151], ["worsening", "OBSERVATION_MODIFIER", 152, 161], ["dyspnea", "OBSERVATION", 165, 172], ["chest", "ANATOMY", 194, 199]]]], "871eb9f53e30a9b67bd226ca8235a50c576a2755": [["Nucleic acid extraction and qRt pCR.", [["Nucleic acid", "CHEMICAL", 0, 12], ["Nucleic acid", "SIMPLE_CHEMICAL", 0, 12], ["Nucleic acid extraction", "TREATMENT", 0, 23], ["qRt pCR", "TEST", 28, 35]]], ["Total nucleic acid content was extracted from 500 microliters of the Virocult medium using NucliSENS easyMAG (BioMerieux, France).", [["nucleic acid", "CHEMICAL", 6, 18], ["nucleic acid", "SIMPLE_CHEMICAL", 6, 18], ["Total nucleic acid content", "PROBLEM", 0, 26], ["the Virocult medium", "TREATMENT", 65, 84], ["NucliSENS easyMAG", "TREATMENT", 91, 108], ["nucleic", "OBSERVATION", 6, 13], ["acid content", "OBSERVATION", 14, 26]]], ["The presence of respiratory viruses was determined by TaqMan Chemistry using the ABI 7500 instrument.", [["respiratory viruses", "DISEASE", 16, 35], ["respiratory viruses", "PROBLEM", 16, 35], ["TaqMan Chemistry", "TEST", 54, 70], ["the ABI", "TEST", 77, 84], ["respiratory viruses", "OBSERVATION", 16, 35]]], ["As part of community influenza surveillance, RNA viruses detection was performed using a panel of real-time reverse transcription-polymerase chain reaction (rRT-PCR) assays, as previously described: influenza A and B 13 , influenza A(H1N1)pdm09 14, 15 and respiratory syncytial virus (RSV) 16 .", [["influenza A", "DISEASE", 199, 210], ["influenza A", "DISEASE", 222, 233], ["respiratory syncytial virus", "DISEASE", 256, 283], ["influenza A", "ORGANISM", 199, 210], ["B 13", "ORGANISM", 215, 219], ["influenza A(H1N1)pdm09 14", "ORGANISM", 222, 247], ["respiratory syncytial virus", "ORGANISM", 256, 283], ["RSV", "ORGANISM", 285, 288], ["influenza A(H1N1", "SPECIES", 222, 238], ["respiratory syncytial virus", "SPECIES", 256, 283], ["respiratory syncytial virus", "SPECIES", 256, 283], ["RSV", "SPECIES", 285, 288], ["community influenza surveillance", "TEST", 11, 43], ["RNA viruses detection", "TEST", 45, 66], ["a panel", "TEST", 87, 94], ["polymerase chain reaction", "PROBLEM", 130, 155], ["rRT-PCR) assays", "TEST", 157, 172], ["influenza A", "TEST", 199, 210], ["influenza", "PROBLEM", 222, 231], ["pdm09", "TEST", 239, 244], ["respiratory syncytial virus (RSV)", "TREATMENT", 256, 289]]], ["Then, samples were tested for presence of: human metapneumovirus 17 , enterovirus 18 , rhinovirus 19 , parainfluenza 3 20 and coronaviruses 21 .", [["samples", "ANATOMY", 6, 13], ["human metapneumovirus 17", "ORGANISM", 43, 67], ["enterovirus 18", "ORGANISM", 70, 84], ["rhinovirus 19", "ORGANISM", 87, 100], ["parainfluenza 3 20", "ORGANISM", 103, 121], ["coronaviruses", "ORGANISM", 126, 139], ["human", "SPECIES", 43, 48], ["metapneumovirus", "SPECIES", 49, 64], ["parainfluenza", "SPECIES", 103, 116], ["human metapneumovirus", "SPECIES", 43, 64], ["samples", "TEST", 6, 13], ["human metapneumovirus", "TEST", 43, 64], ["enterovirus", "TEST", 70, 81], ["rhinovirus", "TEST", 87, 97], ["parainfluenza", "TEST", 103, 116], ["coronaviruses", "PROBLEM", 126, 139]]], ["RT-PCR was performed to detect DNA virus adenovirus 22 and bocavirus 23 .", [["DNA", "CELLULAR_COMPONENT", 31, 34], ["virus adenovirus 22", "ORGANISM", 35, 54], ["bocavirus 23", "ORGANISM", 59, 71], ["RT-PCR", "TEST", 0, 6], ["DNA virus adenovirus", "PROBLEM", 31, 51], ["bocavirus", "TEST", 59, 68]]]], "PMC7341046": [["IntroductionSince the emergence of the COVID-19 pandemic, reports from across the globe suggest that chemosensory loss is among the cardinal symptoms of active infection [[1], [2], [3], [4]].", [["chemosensory loss", "DISEASE", 101, 118], ["infection", "DISEASE", 160, 169], ["[[1], [2], [3], [4]", "SIMPLE_CHEMICAL", 170, 189], ["the COVID", "TEST", 35, 44], ["chemosensory loss", "PROBLEM", 101, 118], ["the cardinal symptoms", "PROBLEM", 128, 149], ["active infection", "PROBLEM", 153, 169], ["globe", "ANATOMY", 82, 87], ["chemosensory loss", "OBSERVATION", 101, 118], ["active", "OBSERVATION_MODIFIER", 153, 159], ["infection", "OBSERVATION", 160, 169]]], ["These findings led major health organizations worldwide to include acute loss of smell and taste as symptoms sufficiently indicative of COVID-19 infection to warrant evaluation.", [["loss of smell", "DISEASE", 73, 86], ["infection", "DISEASE", 145, 154], ["acute loss of smell and taste", "PROBLEM", 67, 96], ["symptoms", "PROBLEM", 100, 108], ["COVID-19 infection", "PROBLEM", 136, 154], ["evaluation", "TEST", 166, 176], ["acute", "OBSERVATION_MODIFIER", 67, 72], ["loss", "OBSERVATION", 73, 77], ["infection", "OBSERVATION", 145, 154]]], ["However, little is known about the natural course of these deficits including their potential for recovery.", [["these deficits", "PROBLEM", 53, 67]]], ["Given significant quality of life and safety impacts of such deficits, prognostic information would benefit patients and their healthcare providers [5].", [["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["such deficits", "PROBLEM", 56, 69]]], ["We present one-month follow-up data from a large, prospectively collected nationwide patient cohort with smell and taste losses during the COVID-19 pandemic.MethodsA web-based survey was opened to patients nationwide with sudden changes in smell and taste since January 2020.", [["smell and taste losses", "DISEASE", 105, 127], ["patient", "ORGANISM", 85, 92], ["patients", "ORGANISM", 197, 205], ["patient", "SPECIES", 85, 92], ["patients", "SPECIES", 197, 205], ["smell", "PROBLEM", 105, 110], ["taste losses", "PROBLEM", 115, 127], ["the COVID", "TEST", 135, 144], ["pandemic", "PROBLEM", 148, 156], ["sudden changes in smell and taste", "PROBLEM", 222, 255], ["large", "OBSERVATION_MODIFIER", 43, 48]]], ["Following consent, patient demographics, associated symptoms, comorbidities, testing status, treatment, and recovery status were collected and managed using REDCap electronic data capture tool [6,7].", [["patient", "ORGANISM", 19, 26], ["patient", "SPECIES", 19, 26], ["associated symptoms", "PROBLEM", 41, 60], ["comorbidities", "PROBLEM", 62, 75], ["testing status", "TEST", 77, 91], ["treatment", "TREATMENT", 93, 102]]], ["Inclusion criteria were age \u2265 18 years and smell or taste changes since January 1, 2020; those with documented negative COVID-19 tests were excluded.", [["COVID", "TEST", 120, 125]]], ["This study was approved by Virginia Commonwealth University Institutional Review Board (HM20019186).ResultsThrough June 7, 2020, 549 individuals meeting inclusion criteria completed the initial survey, 295 (53.7%) completed the 14-day follow-up, and 202 (36.8%) completed the 1-month follow-up.", [["individuals", "ORGANISM", 133, 144], ["This study", "TEST", 0, 10]]], ["Among the 549 respondents, 260 (47.4%) were COVID-19-positive (C+) by testing or diagnosed by a medical professional, and 289 (52.6%) not tested/diagnosed.", [["COVID", "TEST", 44, 49]]], ["Within the C+ cohort, 19.2% completed survey within 1\u20136 days of diagnosis, 51.2% within 1\u20134 weeks, 26.9% within 1\u20132 months, and 2.7% within 3\u20136 months.", [["diagnosis", "TEST", 64, 73]]]], "PMC7521554": [], "0f64dde3074296dee39c524206fbbee41b7ef57b": [["VIRMET 01395Blocking ELISA for distinguishing infectious bovine rhinotracheitis virus (IBRV)-infected animals from those vaccinated with a gene-deleted marker vaccine Saul Kit\", Haruki Otsuka\" and Malon KitbSummaryA sensitive and specific blocking enzyme-linked immunosorbent assay (ELISA) was developed to distinguish infectious bovine rhinotracheitis virus (IBRV)-infected animals from those immunized with a glycoprotein &III deletion mutant, IBRV(NG)dltkdlgIII.SummaryFor this ELISA, undiluted test sera are used to block the binding of an anti-IBRV gII1 monoclonal antibody (mAbgIII)-horseradish peroxidase (HRPO) conjugate to ~111 antigen.", [["sera", "ANATOMY", 503, 507], ["VIRMET 01395", "CHEMICAL", 0, 12], ["infectious bovine rhinotracheitis virus (IBRV)-infected", "DISEASE", 46, 101], ["KitbSummaryA", "CHEMICAL", 203, 215], ["bovine rhinotracheitis virus (IBRV)-infected", "DISEASE", 330, 374], ["bovine", "ORGANISM", 57, 63], ["rhinotracheitis virus", "ORGANISM", 64, 85], ["IBRV", "ORGANISM", 87, 91], ["animals", "ORGANISM", 102, 109], ["bovine", "ORGANISM", 330, 336], ["rhinotracheitis virus", "ORGANISM", 337, 358], ["IBRV", "ORGANISM", 360, 364], ["animals", "ORGANISM", 375, 382], ["&III", "GENE_OR_GENE_PRODUCT", 424, 428], ["sera", "ORGANISM_SUBSTANCE", 503, 507], ["mAbgIII", "SIMPLE_CHEMICAL", 580, 587], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 589, 611], ["HRPO", "SIMPLE_CHEMICAL", 613, 617], ["~111 antigen", "GENE_OR_GENE_PRODUCT", 632, 644], ["glycoprotein &III deletion mutant", "PROTEIN", 411, 444], ["IBRV(NG)dltkdlgIII", "PROTEIN", 446, 464], ["anti-IBRV gII1 monoclonal antibody", "PROTEIN", 544, 578], ["mAbgIII", "PROTEIN", 580, 587], ["horseradish peroxidase (HRPO) conjugate", "PROTEIN", 589, 628], ["~111 antigen", "PROTEIN", 632, 644], ["bovine", "SPECIES", 57, 63], ["rhinotracheitis virus", "SPECIES", 64, 85], ["bovine", "SPECIES", 330, 336], ["rhinotracheitis virus", "SPECIES", 337, 358], ["horseradish", "SPECIES", 589, 600], ["bovine rhinotracheitis virus", "SPECIES", 57, 85], ["IBRV", "SPECIES", 87, 91], ["bovine rhinotracheitis virus", "SPECIES", 330, 358], ["IBRV", "SPECIES", 360, 364], ["anti-IBRV", "SPECIES", 544, 553], ["Blocking ELISA", "TEST", 12, 26], ["infectious bovine rhinotracheitis virus", "PROBLEM", 46, 85], ["infected animals", "PROBLEM", 93, 109], ["a gene-deleted marker vaccine", "TREATMENT", 137, 166], ["Malon KitbSummaryA", "TEST", 197, 215], ["specific blocking enzyme", "TEST", 230, 254], ["immunosorbent assay", "TEST", 262, 281], ["ELISA", "TEST", 283, 288], ["infectious bovine rhinotracheitis virus", "PROBLEM", 319, 358], ["infected animals", "PROBLEM", 366, 382], ["a glycoprotein &III deletion mutant", "TREATMENT", 409, 444], ["IBRV(NG)dltkdlgIII", "TREATMENT", 446, 464], ["this ELISA", "TEST", 476, 486], ["undiluted test sera", "TEST", 488, 507], ["an anti-IBRV gII1 monoclonal antibody", "TEST", 541, 578], ["infectious", "OBSERVATION_MODIFIER", 319, 329]]], ["TMB substrate is used for color development.SummaryNegative S/N values (defined as the absorbance at 650 nm of test sera/absorbance at 650 nm of negative control sera) of >0.80 were obtained with immune sera from gnotobiotic cattle immunized with several bovine viruses, with bovine antisera to bovine herpesvirus-2, and vesicular stomatitis virus, with porcine antisera to pseudorabies virus and parvovirus, and with normal sera from heterologous species.", [["sera", "ANATOMY", 116, 120], ["sera", "ANATOMY", 162, 166], ["sera", "ANATOMY", 203, 207], ["sera", "ANATOMY", 425, 429], ["vesicular stomatitis", "DISEASE", 321, 341], ["TMB", "CHEMICAL", 0, 3], ["TMB", "SIMPLE_CHEMICAL", 0, 3], ["sera", "ORGANISM_SUBSTANCE", 203, 207], ["cattle", "ORGANISM", 225, 231], ["bovine", "ORGANISM", 255, 261], ["bovine", "ORGANISM", 276, 282], ["bovine herpesvirus-2", "ORGANISM", 295, 315], ["vesicular stomatitis virus", "ORGANISM", 321, 347], ["porcine", "ORGANISM", 354, 361], ["pseudorabies virus", "ORGANISM", 374, 392], ["parvovirus", "ORGANISM", 397, 407], ["sera", "ORGANISM_SUBSTANCE", 425, 429], ["cattle", "SPECIES", 225, 231], ["bovine", "SPECIES", 255, 261], ["bovine", "SPECIES", 276, 282], ["bovine", "SPECIES", 295, 301], ["herpesvirus-2", "SPECIES", 302, 315], ["vesicular stomatitis virus", "SPECIES", 321, 347], ["porcine", "SPECIES", 354, 361], ["pseudorabies virus", "SPECIES", 374, 392], ["cattle", "SPECIES", 225, 231], ["bovine", "SPECIES", 255, 261], ["bovine", "SPECIES", 276, 282], ["bovine herpesvirus-2", "SPECIES", 295, 315], ["vesicular stomatitis virus", "SPECIES", 321, 347], ["porcine", "SPECIES", 354, 361], ["pseudorabies virus", "SPECIES", 374, 392], ["TMB substrate", "TREATMENT", 0, 13], ["the absorbance", "TEST", 83, 97], ["test sera", "TEST", 111, 120], ["absorbance", "TEST", 121, 131], ["sera", "TEST", 162, 166], ["immune sera", "PROBLEM", 196, 207], ["gnotobiotic cattle", "TREATMENT", 213, 231], ["several bovine viruses", "PROBLEM", 247, 269], ["bovine antisera", "TREATMENT", 276, 291], ["bovine herpesvirus", "TEST", 295, 313], ["vesicular stomatitis virus", "PROBLEM", 321, 347], ["porcine antisera", "TREATMENT", 354, 370], ["pseudorabies virus", "PROBLEM", 374, 392], ["parvovirus", "PROBLEM", 397, 407], ["vesicular stomatitis", "ANATOMY", 321, 341]]], ["Negative S/N values were also obtained with sera from rabbits twice vaccinated with IBRV(NG)dltkdlgIII.", [["sera", "ANATOMY", 44, 48], ["NG", "CHEMICAL", 89, 91], ["sera", "ORGANISM_SUBSTANCE", 44, 48], ["rabbits", "ORGANISM", 54, 61], ["rabbits", "SPECIES", 54, 61], ["rabbits", "SPECIES", 54, 61], ["IBRV", "SPECIES", 84, 88], ["S/N values", "TEST", 9, 19], ["sera", "TEST", 44, 48], ["IBRV(NG)dltkdlgIII", "TREATMENT", 84, 102]]], ["However, the S/N values became positive (S/N <0.8) IO to 17 days after the rabbits were challenge exposed to virulent IBRV(Cooper).SummaryMost of 116 sera (84%) from feedlot cattle with virus neutralization (VN) titers of < 1:2 or < 1:4 had negative S/N values > 0.8, but 18 sera with negative VN titers had positive S/N values, consistent with observations indicating that an IBRV outbreak was occurring in one of the feedlot herds.", [["sera", "ANATOMY", 150, 154], ["sera", "ANATOMY", 275, 279], ["rabbits", "ORGANISM", 75, 82], ["sera", "ORGANISM_SUBSTANCE", 150, 154], ["cattle", "ORGANISM", 174, 180], ["sera", "ORGANISM_SUBSTANCE", 275, 279], ["VN", "GENE_OR_GENE_PRODUCT", 294, 296], ["rabbits", "SPECIES", 75, 82], ["cattle", "SPECIES", 174, 180], ["rabbits", "SPECIES", 75, 82], ["IBRV", "SPECIES", 118, 122], ["cattle", "SPECIES", 174, 180], ["IBRV", "SPECIES", 377, 381], ["the S/N values", "TEST", 9, 23], ["positive", "PROBLEM", 31, 39], ["the rabbits", "TREATMENT", 71, 82], ["sera", "TEST", 150, 154], ["virus neutralization", "TREATMENT", 186, 206], ["titers", "TEST", 212, 218], ["S/N values", "TEST", 250, 260], ["sera", "TEST", 275, 279], ["VN titers", "TEST", 294, 303], ["positive S/N values", "PROBLEM", 308, 327], ["an IBRV outbreak", "PROBLEM", 374, 390], ["consistent with", "UNCERTAINTY", 329, 344]]], ["Thirty nine sera (98%) from feedlot cattle with VN titers of 1:2 to 1:128 had positive S/N values (x0.8).", [["sera", "ANATOMY", 12, 16], ["sera", "ORGANISM_SUBSTANCE", 12, 16], ["cattle", "ORGANISM", 36, 42], ["cattle", "SPECIES", 36, 42], ["feedlot", "SPECIES", 28, 35], ["cattle", "SPECIES", 36, 42], ["Thirty nine sera", "TEST", 0, 16], ["feedlot cattle", "TEST", 28, 42], ["VN titers", "TEST", 48, 57], ["positive S/N values", "PROBLEM", 78, 97]]], ["One serum with a VN titer of 1:2 had a borderline ( + ) S/N value of 0.8 1.", [["serum", "ANATOMY", 4, 9], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["One serum", "TEST", 0, 9], ["a VN titer", "TEST", 15, 25], ["S/N value", "TEST", 56, 65]]], ["After immunization with a commercial gIII-IntroductionThe herpesvirus (bovine herpesvirus-I; BHV-1) associated with infectious bovine rhinotracheitis (IBR) is an important pathogen of cattle, which causes severe respiratory infections, conjunctivitis, encephalitis, loss of milk yield. metritis, enteritis, infectious pustuiar vulvovaginitisj' balanoposthitis (IPV; IPB), and abortions (Gibbs and Reyemamu, 1977) .", [["respiratory", "ANATOMY", 212, 223], ["milk", "ANATOMY", 274, 278], ["infectious bovine rhinotracheitis", "DISEASE", 116, 149], ["IBR", "DISEASE", 151, 154], ["respiratory infections", "DISEASE", 212, 234], ["conjunctivitis", "DISEASE", 236, 250], ["encephalitis", "DISEASE", 252, 264], ["loss of milk yield", "DISEASE", 266, 284], ["metritis", "DISEASE", 286, 294], ["enteritis", "DISEASE", 296, 305], ["infectious pustuiar vulvovaginitisj' balanoposthitis (IPV; IPB), and abortions", "DISEASE", 307, 385], ["herpesvirus", "ORGANISM", 58, 69], ["bovine herpesvirus-I; BHV-1", "ORGANISM", 71, 98], ["bovine rhinotracheitis", "ORGANISM", 127, 149], ["IBR", "ORGANISM", 151, 154], ["cattle", "ORGANISM", 184, 190], ["milk", "ORGANISM_SUBSTANCE", 274, 278], ["bovine", "SPECIES", 71, 77], ["BHV-1", "SPECIES", 93, 98], ["bovine", "SPECIES", 127, 133], ["rhinotracheitis", "SPECIES", 134, 149], ["cattle", "SPECIES", 184, 190], ["bovine herpesvirus-I; BHV-1", "SPECIES", 71, 98], ["bovine rhinotracheitis", "SPECIES", 127, 149], ["IBR", "SPECIES", 151, 154], ["cattle", "SPECIES", 184, 190], ["immunization", "TREATMENT", 6, 18], ["a commercial gIII", "TREATMENT", 24, 41], ["The herpesvirus (bovine herpesvirus", "TEST", 54, 89], ["BHV", "TEST", 93, 96], ["infectious bovine rhinotracheitis", "PROBLEM", 116, 149], ["severe respiratory infections", "PROBLEM", 205, 234], ["conjunctivitis", "PROBLEM", 236, 250], ["encephalitis", "PROBLEM", 252, 264], ["loss of milk yield", "PROBLEM", 266, 284], ["metritis", "PROBLEM", 286, 294], ["enteritis", "PROBLEM", 296, 305], ["infectious pustuiar vulvovaginitisj", "PROBLEM", 307, 342], ["' balanoposthitis", "PROBLEM", 342, 359], ["abortions", "PROBLEM", 376, 385], ["infectious", "OBSERVATION_MODIFIER", 116, 126], ["bovine rhinotracheitis", "OBSERVATION", 127, 149], ["severe", "OBSERVATION_MODIFIER", 205, 211], ["respiratory", "ANATOMY", 212, 223], ["infections", "OBSERVATION", 224, 234], ["conjunctivitis", "OBSERVATION", 236, 250], ["encephalitis", "OBSERVATION", 252, 264], ["enteritis", "OBSERVATION", 296, 305], ["infectious", "OBSERVATION_MODIFIER", 307, 317]]], ["IBRV (BHV-I) was first isolated in the 1950s.", [["IBRV", "GENE_OR_GENE_PRODUCT", 0, 4], ["BHV-I", "ORGANISM", 6, 11], ["IBRV", "SPECIES", 0, 4], ["BHV-I", "SPECIES", 6, 11], ["IBRV", "TEST", 0, 4]]], ["However, it was not until the 196Os, with increasing population stress in livestock production. that the severe respiratory aspects of IBRV infection became increasingly prominent in USA feedlots along with conjunctivitis in calves and abortion storms in in-contact cows.", [["respiratory", "ANATOMY", 112, 123], ["IBRV infection", "DISEASE", 135, 149], ["conjunctivitis", "DISEASE", 207, 221], ["calves", "ORGANISM", 225, 231], ["cows", "ORGANISM", 266, 270], ["calves", "SPECIES", 225, 231], ["IBRV", "SPECIES", 135, 139], ["increasing population stress", "PROBLEM", 42, 70], ["the severe respiratory aspects", "PROBLEM", 101, 131], ["IBRV infection", "PROBLEM", 135, 149], ["conjunctivitis", "PROBLEM", 207, 221], ["increasing", "OBSERVATION_MODIFIER", 42, 52], ["population", "OBSERVATION", 53, 63], ["livestock production", "OBSERVATION", 74, 94], ["severe", "OBSERVATION_MODIFIER", 105, 111], ["respiratory", "OBSERVATION_MODIFIER", 112, 123], ["infection", "OBSERVATION", 140, 149], ["prominent", "OBSERVATION_MODIFIER", 170, 179], ["conjunctivitis", "OBSERVATION", 207, 221], ["calves", "ANATOMY", 225, 231]]], ["I3eginning about 1972, the more severe respiratory form of IBR also became widespread in western European countries (Edwards, 198X; Ackermann et al..", [["IBR", "DISEASE", 59, 62], ["widespread", "OBSERVATION_MODIFIER", 75, 85]]], ["1990a.h.) .IntroductionVarious methods have been used to diagnose and control IBR.", [["IBR", "DISEASE", 78, 81], ["IntroductionVarious methods", "TREATMENT", 11, 38]]], ["In some countries, test and slaughter policies have been followed.", [["test and slaughter policies", "TEST", 19, 46]]], ["In others, modifiedlive and killed IBRV vaccines have been used to control disease.", [["IBRV", "SPECIES", 35, 39], ["modifiedlive and killed IBRV vaccines", "TREATMENT", 11, 48], ["disease", "PROBLEM", 75, 82]]], ["However. despite the various control programs.", [["the various control programs", "TREATMENT", 17, 45]]], ["IBR has continued to increase.", [["IBR", "DISEASE", 0, 3], ["IBR", "PROBLEM", 0, 3], ["increase", "OBSERVATION_MODIFIER", 21, 29]]], ["This could further accelerate the spread of disease.", [["disease", "PROBLEM", 44, 51], ["spread", "OBSERVATION_MODIFIER", 34, 40], ["disease", "OBSERVATION", 44, 51]]], ["Hence, there is an urgent need for better control and eradication programs (Ackermann et al..", [["eradication programs", "TREATMENT", 54, 74]]], ["1990a,b) .IntroductionIn Switzerland, with a national herd consisting of about 2000000 cattle including more than 800 000 breeding animals, a test and slaughter eradication program was initiated 10 years ago.", [["cattle", "SPECIES", 87, 93], ["cattle", "SPECIES", 87, 93], ["a test", "TEST", 140, 146], ["slaughter eradication program", "TREATMENT", 151, 180]]], ["Although appropriate for small countries like Switzerland, it seems unlikely that similar test and slaughter programs would be feasible or cost-effective in countries with much larger cattle herds.", [["cattle", "SPECIES", 184, 190], ["cattle", "SPECIES", 184, 190]]], ["Thus. alternative approaches are needed.", [["alternative approaches", "TREATMENT", 6, 28]]], ["One such approach now under consideration is that of vaccinating cattle with genetically engineered deletion marker vaccines so as to protect the cattle, and then testing the cattle with differential diagnostic test kits so that infected animals may be distinguished from vaccinated anin?& and culled from the herd (Kit et al., 1990b) .", [["cattle", "ORGANISM", 65, 71], ["cattle", "ORGANISM", 146, 152], ["cattle", "ORGANISM", 175, 181], ["cattle", "SPECIES", 65, 71], ["cattle", "SPECIES", 146, 152], ["cattle", "SPECIES", 175, 181], ["cattle", "SPECIES", 65, 71], ["cattle", "SPECIES", 146, 152], ["cattle", "SPECIES", 175, 181], ["genetically engineered deletion marker vaccines", "TREATMENT", 77, 124], ["diagnostic test kits", "TEST", 200, 220]]], ["The genedeleted marker vaccine and differential diagnostic test approach has already been used in worldwide pseudorabies control and eradication programs (Kit, S. and Kit, M., 1991) .IntroductionModified-live IBRV vaccines attenuated through the functional inactivation of the thymidine kinase (TK) gene have been described (Kit, 1988 (Kit, , 1989 Kit et al., 1985 Kit et al., , 1986 Kit et al., , 1991 .", [["thymidine", "CHEMICAL", 277, 286], ["thymidine", "CHEMICAL", 277, 286], ["pseudorabies", "ORGANISM", 108, 120], ["IBRV", "ORGANISM", 209, 213], ["thymidine kinase", "GENE_OR_GENE_PRODUCT", 277, 293], ["thymidine kinase (TK) gene", "DNA", 277, 303], ["pseudorabies", "SPECIES", 108, 120], ["The genedeleted marker vaccine", "TREATMENT", 0, 30], ["differential diagnostic test approach", "TEST", 35, 72], ["worldwide pseudorabies control", "TREATMENT", 98, 128], ["eradication programs", "TREATMENT", 133, 153], ["IntroductionModified-live IBRV vaccines", "TREATMENT", 183, 222], ["the thymidine kinase", "TEST", 273, 293]]], ["In vivo studies have shown that TK-negative IBRV vaccines can protect cattle against clinical signs of disease and suggest that they may be administered safely to pregnant cows (Kit et al., 1986; Miiler et al., 1991) .", [["TK", "GENE_OR_GENE_PRODUCT", 32, 34], ["IBRV", "ORGANISM", 44, 48], ["cattle", "ORGANISM", 70, 76], ["cows", "ORGANISM", 172, 176], ["cattle", "SPECIES", 70, 76], ["cows", "SPECIES", 172, 176], ["IBRV", "SPECIES", 44, 48], ["cattle", "SPECIES", 70, 76], ["vivo studies", "TEST", 3, 15], ["TK", "TEST", 32, 34], ["IBRV vaccines", "TREATMENT", 44, 57], ["disease", "PROBLEM", 103, 110], ["disease", "OBSERVATION", 103, 110]]], ["It may be noted that extensive field usage had also shown that TK-negative pseudorabies vaccines are efficacious and safe for newborn piglets and for sows in all stages of gestation (Kit, S. and Kit, M., 1991) .", [["pseudorabies", "ORGANISM", 75, 87], ["piglets", "ORGANISM", 134, 141], ["piglets", "SPECIES", 134, 141], ["pseudorabies", "SPECIES", 75, 87], ["TK", "TEST", 63, 65], ["pseudorabies vaccines", "TREATMENT", 75, 96], ["newborn piglets", "TREATMENT", 126, 141]]], ["Starting with the parental TK-deleted IBRV, a second generation IBRV marker vaccine with a deletion mutation in a major IBRV glycoprotein gene, that is, gIII, has now been developed (Kit et al., 1990b) .", [["IBRV", "CELL", 38, 42], ["IBRV glycoprotein", "GENE_OR_GENE_PRODUCT", 120, 137], ["parental TK-deleted IBRV", "DNA", 18, 42], ["IBRV glycoprotein gene", "DNA", 120, 142], ["gIII", "DNA", 153, 157], ["a second generation IBRV marker vaccine", "TREATMENT", 44, 83], ["a deletion mutation", "PROBLEM", 89, 108]]], ["The present study describes a gIII blocking ELISA test for use in conjunction with the gII1 gene-deleted IBRV marker vaccine.IntroductionELISA tests for the detection of IBRV have previously been described (Bolton et al., 1981; Collins et al., 198411985, 1985) .", [["gIII", "SIMPLE_CHEMICAL", 30, 34], ["gII1", "GENE_OR_GENE_PRODUCT", 87, 91], ["IBRV", "CANCER", 170, 174], ["gII1 gene", "DNA", 87, 96], ["IBRV", "DNA", 170, 174], ["IBRV", "SPECIES", 170, 174], ["The present study", "TEST", 0, 17], ["a gIII blocking ELISA test", "TEST", 28, 54], ["the gII1 gene-deleted IBRV marker vaccine", "TREATMENT", 83, 124], ["IntroductionELISA tests", "TEST", 125, 148], ["the detection", "TEST", 153, 166], ["IBRV", "PROBLEM", 170, 174]]], ["However, to our knowledge, this is the first description of a differential IBRV ELISA test for use with a vaccine marker._Materials and MethodsTriton X-100 extracts were prepared from the gIII-positive IBRV(NG)dltk parental virus, as described (Kit et al., 1990a) , and diluted 1:1600 (as determined by a titration trial coating process) with KPL (Kirkegaard and Perry Laboratories, Gaithersburg, MD) coating buffer, which contains 0.01 M phosphate-buffered saline.", [["extracts", "ANATOMY", 156, 164], ["MethodsTriton X-100", "CHEMICAL", 136, 155], ["NG", "CHEMICAL", 207, 209], ["KPL", "CHEMICAL", 343, 346], ["phosphate", "CHEMICAL", 439, 448], ["phosphate", "CHEMICAL", 439, 448], ["gIII", "GENE_OR_GENE_PRODUCT", 188, 192], ["IBRV", "ORGANISM", 202, 206], ["KPL", "SIMPLE_CHEMICAL", 343, 346], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 439, 464], ["IBRV", "SPECIES", 75, 79], ["a vaccine marker", "TREATMENT", 104, 120], ["Materials", "TREATMENT", 122, 131], ["MethodsTriton X-100 extracts", "TREATMENT", 136, 164], ["dltk parental virus", "PROBLEM", 210, 229], ["a titration trial coating process", "TREATMENT", 303, 336], ["0.01 M phosphate", "TREATMENT", 432, 448], ["buffered saline", "TREATMENT", 449, 464]]], ["Then, 0.1 ml ahquots were added to wells of 96-well flat-bottomed microtiter plates.", [["bottomed microtiter plates", "TREATMENT", 57, 83]]], ["The plates were incubated overnight at 4\"C, the supernatant fluids were removed, and 0.3 ml KPL blocking solution (which contains 1% bovine serum albumin in phosphate buffer) was added to each well, and the plates were further incubated overnight at 4\u00b0C. The supernatant was again dumped and the wells were rinsed three times with TEN buffer, (6.05 g Trizma, 0.38 g NazEDTA, 8.76 g NaCl in I liter of water adjusted to a pH of 7.2).", [["supernatant fluids", "ANATOMY", 48, 66], ["serum", "ANATOMY", 140, 145], ["supernatant", "ANATOMY", 259, 270], ["phosphate", "CHEMICAL", 157, 166], ["NazEDTA", "CHEMICAL", 366, 373], ["NaCl", "CHEMICAL", 382, 386], ["phosphate", "CHEMICAL", 157, 166], ["NazEDTA", "CHEMICAL", 366, 373], ["NaCl", "CHEMICAL", 382, 386], ["KPL", "SIMPLE_CHEMICAL", 92, 95], ["bovine", "ORGANISM", 133, 139], ["serum", "ORGANISM_SUBSTANCE", 140, 145], ["albumin", "GENE_OR_GENE_PRODUCT", 146, 153], ["phosphate", "SIMPLE_CHEMICAL", 157, 166], ["bovine", "SPECIES", 133, 139], ["The plates", "TREATMENT", 0, 10], ["the supernatant fluids", "TREATMENT", 44, 66], ["0.3 ml KPL blocking solution", "TREATMENT", 85, 113], ["1% bovine serum albumin in phosphate buffer", "TREATMENT", 130, 173], ["the plates", "TREATMENT", 203, 213], ["The supernatant", "TREATMENT", 255, 270], ["the wells", "TREATMENT", 292, 301], ["TEN buffer", "TREATMENT", 331, 341], ["NazEDTA", "TREATMENT", 366, 373], ["NaCl in I liter of water", "TREATMENT", 382, 406], ["a pH", "TEST", 419, 423]]], ["The plates were then tapped dry and stored at -20\u00b0C (Kit, M. and Kit, S., 1991).", [["The plates", "TREATMENT", 0, 10], ["plates", "OBSERVATION_MODIFIER", 4, 10], ["tapped", "OBSERVATION_MODIFIER", 21, 27], ["dry", "OBSERVATION", 28, 31]]], ["Coating buffer was added to wells designated as blank wells, but IBRV antigen was omitted.", [["IBRV antigen", "GENE_OR_GENE_PRODUCT", 65, 77], ["IBRV antigen", "PROTEIN", 65, 77], ["IBRV", "SPECIES", 65, 69], ["Coating buffer", "TREATMENT", 0, 14], ["IBRV antigen", "TEST", 65, 77]]], ["Otherwise, the blank wells were processed in the same way as the other wells.Description of seraGnotobiotic (G) antisera and virus antisera raised in normal calves were supplied by the NVSL-USDA and had the following VN titers: bovine viral diarrhea (G~, VN ~ 164, and FASN titer (NADL) -1: 1024; bovine herpes-l, VN -~ I :64: bovine herpesvirus-2, IFA titer 3 1:2048; bovine ~oronavirus{G), IFA titer 12560: vesicular stomatitis (Indiana), VN 3 1:512; vesicular stomatitis (New Jersey), VN 3 I:5 12; bovine respiratory syncytial virus(G), VN 1: 128; and parainfluenza_3(G), IFA titer -1:2560.", [["vesicular", "ANATOMY", 409, 418], ["vesicular", "ANATOMY", 453, 462], ["viral diarrhea", "DISEASE", 235, 249], ["vesicular stomatitis", "DISEASE", 409, 429], ["vesicular stomatitis", "DISEASE", 453, 473], ["respiratory syncytial virus", "DISEASE", 508, 535], ["seraGnotobiotic (G) antisera", "GENE_OR_GENE_PRODUCT", 92, 120], ["calves", "ORGANISM", 157, 163], ["bovine", "ORGANISM", 228, 234], ["FASN", "GENE_OR_GENE_PRODUCT", 269, 273], ["bovine", "ORGANISM", 297, 303], ["bovine herpesvirus-2", "ORGANISM", 327, 347], ["bovine", "ORGANISM", 369, 375], ["IFA", "ORGANISM", 392, 395], ["vesicular stomatitis", "ORGANISM", 409, 429], ["vesicular stomatitis", "ORGANISM", 453, 473], ["bovine", "ORGANISM", 501, 507], ["respiratory syncytial virus", "ORGANISM", 508, 535], ["seraGnotobiotic (G) antisera", "PROTEIN", 92, 120], ["calves", "SPECIES", 157, 163], ["bovine", "SPECIES", 228, 234], ["bovine", "SPECIES", 297, 303], ["bovine", "SPECIES", 327, 333], ["bovine", "SPECIES", 369, 375], ["bovine", "SPECIES", 501, 507], ["respiratory syncytial virus", "SPECIES", 508, 535], ["bovine respiratory syncytial virus", "SPECIES", 501, 535], ["seraGnotobiotic (G) antisera", "TREATMENT", 92, 120], ["virus antisera", "TEST", 125, 139], ["VN titers", "TEST", 217, 226], ["bovine viral diarrhea", "PROBLEM", 228, 249], ["G", "TEST", 251, 252], ["VN", "TEST", 255, 257], ["FASN titer", "TEST", 269, 279], ["bovine herpes-l", "TEST", 297, 312], ["bovine herpesvirus", "TEST", 327, 345], ["IFA titer", "TEST", 349, 358], ["bovine", "TEST", 369, 375], ["oronavirus", "TEST", 377, 387], ["IFA titer", "TEST", 392, 401], ["vesicular stomatitis", "PROBLEM", 409, 429], ["VN", "TEST", 441, 443], ["vesicular stomatitis", "PROBLEM", 453, 473], ["bovine respiratory syncytial virus", "TEST", 501, 535], ["VN", "TEST", 540, 542], ["parainfluenza_3", "TEST", 555, 570], ["IFA titer", "TEST", 575, 584], ["vesicular stomatitis", "ANATOMY", 409, 429], ["vesicular stomatitis", "ANATOMY", 453, 473], ["respiratory syncytial", "ANATOMY", 508, 529]]], ["The anti-swine PRV, anti-bovine rotovirus, and anti-porcine parvovirus sera were also supplied by the NVSL-USDA (Kit et al., 1990a) .", [["sera", "ANATOMY", 71, 75], ["anti-swine PRV", "ORGANISM", 4, 18], ["anti-bovine rotovirus", "ORGANISM", 20, 41], ["anti-porcine parvovirus", "ORGANISM", 47, 70], ["sera", "ORGANISM_SUBSTANCE", 71, 75], ["anti-porcine parvovirus", "SPECIES", 47, 70], ["PRV", "SPECIES", 15, 18], ["anti-porcine parvovirus", "SPECIES", 47, 70], ["The anti-swine PRV", "TREATMENT", 0, 18], ["anti-bovine rotovirus", "TREATMENT", 20, 41], ["anti-porcine parvovirus sera", "TREATMENT", 47, 75]]], ["Normal lamb, chick, and fetal bovine sera were purchased from GIBCO-BRL (Gaithersburg, MD).", [["lamb", "ANATOMY", 7, 11], ["chick", "ANATOMY", 13, 18], ["fetal bovine sera", "ANATOMY", 24, 41], ["lamb", "ORGANISM_SUBDIVISION", 7, 11], ["chick", "ORGANISM", 13, 18], ["bovine", "ORGANISM", 30, 36], ["sera", "ORGANISM_SUBSTANCE", 37, 41], ["GIBCO-BRL", "CELL", 62, 71], ["lamb", "SPECIES", 7, 11], ["chick", "SPECIES", 13, 18], ["bovine", "SPECIES", 30, 36], ["lamb", "SPECIES", 7, 11], ["bovine", "SPECIES", 30, 36], ["fetal bovine sera", "TEST", 24, 41], ["lamb", "OBSERVATION_MODIFIER", 7, 11]]], ["Horse serum was purchased from Inovar Biologicals, Gaithersburg, MD.", [["serum", "ANATOMY", 6, 11], ["Horse", "ORGANISM", 0, 5], ["serum", "ORGANISM_SUBSTANCE", 6, 11], ["Horse serum", "TEST", 0, 11]]], ["Normal mouse and rabbit sera were obtained from healthy mice and rabbits, respectively.", [["sera", "ANATOMY", 24, 28], ["mouse", "ORGANISM", 7, 12], ["rabbit", "ORGANISM", 17, 23], ["sera", "ORGANISM_SUBSTANCE", 24, 28], ["mice", "ORGANISM", 56, 60], ["rabbits", "ORGANISM", 65, 72], ["mouse", "SPECIES", 7, 12], ["rabbit", "SPECIES", 17, 23], ["mice", "SPECIES", 56, 60], ["rabbits", "SPECIES", 65, 72], ["mouse", "SPECIES", 7, 12], ["rabbit", "SPECIES", 17, 23], ["mice", "SPECIES", 56, 60], ["rabbits", "SPECIES", 65, 72]]], ["Sera from Texas feedlot cattle were obtained by Dr. Stewart McConnell from Dr. Richard Mock.", [["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["cattle", "ORGANISM", 24, 30], ["cattle", "SPECIES", 24, 30], ["cattle", "SPECIES", 24, 30]]], ["Texas Veterinary Medical Diagnostic Laboratory, Amarillo, TX.", [["TX", "TREATMENT", 58, 60]]], ["In addition to sera collected at the time the cattle arrived at the feedlot, sera were collected from some feedlot cattle after immunization with a commercial gIII-positive IBRV vaccine.", [["sera", "ANATOMY", 15, 19], ["sera", "ANATOMY", 77, 81], ["sera", "ORGANISM_SUBSTANCE", 15, 19], ["cattle", "ORGANISM", 46, 52], ["sera", "ORGANISM_SUBSTANCE", 77, 81], ["cattle", "ORGANISM", 115, 121], ["gIII", "GENE_OR_GENE_PRODUCT", 159, 163], ["IBRV", "ORGANISM", 173, 177], ["cattle", "SPECIES", 46, 52], ["cattle", "SPECIES", 115, 121], ["cattle", "SPECIES", 46, 52], ["feedlot", "SPECIES", 107, 114], ["cattle", "SPECIES", 115, 121], ["IBRV", "SPECIES", 173, 177], ["sera", "TEST", 15, 19], ["immunization", "TREATMENT", 128, 140], ["a commercial gIII", "TREATMENT", 146, 163], ["positive IBRV vaccine", "TREATMENT", 164, 185]]], ["VN analyses on the bovine sera were carried out at the Texas Veterinary Medical Diagnostic Laboratory.Description of seraAnti-IRBV gII1 blocking ELISA analyses on all sera were carried out at the Baylor College of Medicine in Houston, Texas.Description of seraAnti-IBRV rabbit sera was prepared as follows: three young female New Zealand rabbits weighing about 1 kg were pre-bled by ear and then inoculated intramuscularly with about 3 x lo3 PFU of the marker vaccine, IBRV(NG)dltkdlgIII.Description of seraThe animals were observed daily for clinical symptoms of disease (Kelly, 1977) .", [["sera", "ANATOMY", 26, 30], ["sera", "ANATOMY", 167, 171], ["sera", "ANATOMY", 277, 281], ["ear", "ANATOMY", 383, 386], ["intramuscularly", "ANATOMY", 407, 422], ["sera", "ANATOMY", 503, 507], ["NG", "CHEMICAL", 474, 476], ["bovine", "ORGANISM", 19, 25], ["sera", "ORGANISM_SUBSTANCE", 26, 30], ["seraAnti-IRBV", "ORGANISM", 117, 130], ["gII1", "GENE_OR_GENE_PRODUCT", 131, 135], ["sera", "ORGANISM_SUBSTANCE", 167, 171], ["rabbit", "ORGANISM", 270, 276], ["sera", "ORGANISM_SUBSTANCE", 277, 281], ["rabbits", "ORGANISM", 338, 345], ["ear", "ORGAN", 383, 386], ["sera", "ORGANISM_SUBSTANCE", 503, 507], ["animals", "ORGANISM", 511, 518], ["VN", "PROTEIN", 0, 2], ["seraAnti-IRBV gII1", "PROTEIN", 117, 135], ["IBRV(NG)dltkdlgIII", "PROTEIN", 469, 487], ["bovine", "SPECIES", 19, 25], ["rabbit", "SPECIES", 270, 276], ["rabbits", "SPECIES", 338, 345], ["bovine", "SPECIES", 19, 25], ["seraAnti-IRBV", "SPECIES", 117, 130], ["IBRV", "SPECIES", 265, 269], ["rabbit", "SPECIES", 270, 276], ["VN analyses", "TEST", 0, 11], ["the bovine sera", "TEST", 15, 30], ["ELISA analyses", "TEST", 145, 159], ["all sera", "TEST", 163, 171], ["New Zealand rabbits weighing", "TREATMENT", 326, 354], ["the marker vaccine", "TREATMENT", 449, 467], ["IBRV(NG)dltkdlgIII", "TREATMENT", 469, 487], ["clinical symptoms of disease", "PROBLEM", 543, 571], ["ear", "ANATOMY", 383, 386]]], ["At 14 days postvaccination, sera were obtained and the rabbits were vaccinated again intramusc~llarly with about 2 x IO3 PFU of IBRV(NG)dltkdlgIII.Description of seraAt 21 days after the second vaccinatioI~, the rabbits were again bled and then challenged intramuscularly with about 3.5 x 10\" PFU of the virulent IBRV(Los Angeles) strain.", [["sera", "ANATOMY", 28, 32], ["NG", "CHEMICAL", 133, 135], ["sera", "ORGANISM_SUBSTANCE", 28, 32], ["rabbits", "ORGANISM", 55, 62], ["rabbits", "ORGANISM", 212, 219], ["IBRV", "ORGANISM", 313, 317], ["rabbits", "SPECIES", 55, 62], ["rabbits", "SPECIES", 212, 219], ["rabbits", "SPECIES", 55, 62], ["rabbits", "SPECIES", 212, 219], ["IBRV", "SPECIES", 313, 317], ["sera", "TEST", 28, 32], ["the second vaccinatioI~", "TREATMENT", 183, 206]]], ["Sera were obtained at 6.", [["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["Sera", "TEST", 0, 4]]], ["The animals remained healthy after vaccination and challenge.", [["animals", "ORGANISM", 4, 11], ["vaccination", "TREATMENT", 35, 46]]], ["Rabbit sera were heated for 30 nun at 58'C, and VN titers were determined by plaque reduction assays as described (Kit et al., 1991) .Description of seraThe procedures used were analogous to those employed previously in the sensitive anti-PRV glycoprotein gII1 blocking ELISA for distinguishi~lg between pseudorabies-infested and vaccinated pigs (Kit et al., 1990a; Kit, M. and Kit S., 1991) .", [["sera", "ANATOMY", 7, 11], ["plaque", "ANATOMY", 77, 83], ["sera", "ANATOMY", 149, 153], ["Rabbit", "ORGANISM", 0, 6], ["sera", "ORGANISM_SUBSTANCE", 7, 11], ["VN", "GENE_OR_GENE_PRODUCT", 48, 50], ["sera", "ORGANISM_SUBSTANCE", 149, 153], ["gII1", "GENE_OR_GENE_PRODUCT", 256, 260], ["pseudorabies", "ORGANISM", 304, 316], ["pigs", "ORGANISM", 341, 345], ["VN", "PROTEIN", 48, 50], ["anti-PRV glycoprotein", "PROTEIN", 234, 255], ["gII1", "PROTEIN", 256, 260], ["Rabbit", "SPECIES", 0, 6], ["pseudorabies", "SPECIES", 304, 316], ["pigs", "SPECIES", 341, 345], ["Rabbit", "SPECIES", 0, 6], ["pseudorabies", "SPECIES", 304, 316], ["pigs", "SPECIES", 341, 345], ["Rabbit sera", "TEST", 0, 11], ["VN titers", "TEST", 48, 57], ["The procedures", "TREATMENT", 153, 167], ["pseudorabies", "PROBLEM", 304, 316]]], ["In each plate, two wells were used as blank wells (lacking antigen}, two wells for negative controls (fetal bovine sera lacking IBRV antibodies), and two wells for positive control (sera with IBRV antibodies).", [["sera", "ANATOMY", 115, 119], ["sera", "ANATOMY", 182, 186], ["bovine", "ORGANISM", 108, 114], ["sera", "ORGANISM_SUBSTANCE", 115, 119], ["IBRV antibodies", "GENE_OR_GENE_PRODUCT", 128, 143], ["sera", "ORGANISM_SUBSTANCE", 182, 186], ["IBRV antibodies", "PROTEIN", 128, 143], ["IBRV antibodies", "PROTEIN", 192, 207], ["bovine", "SPECIES", 108, 114], ["bovine", "SPECIES", 108, 114], ["IBRV", "SPECIES", 192, 196], ["two wells", "TREATMENT", 15, 24], ["fetal bovine sera", "TEST", 102, 119], ["positive control (sera with IBRV antibodies", "PROBLEM", 164, 207], ["plate", "ANATOMY_MODIFIER", 8, 13]]], ["Aliquots (0.1 ml) of test sera or of negative and positive control sera were added to appropriate wells of microtiter test plates.", [["Aliquots", "ANATOMY", 0, 8], ["sera", "ANATOMY", 26, 30], ["sera", "ANATOMY", 67, 71], ["sera", "ORGANISM_SUBSTANCE", 26, 30], ["sera", "ORGANISM_SUBSTANCE", 67, 71], ["test sera", "TEST", 21, 30], ["positive control sera", "PROBLEM", 50, 71], ["microtiter test plates", "TEST", 107, 129]]], ["A negative serum was added to one blank well and a positive serum to the other blank well.", [["serum", "ANATOMY", 11, 16], ["serum", "ANATOMY", 60, 65], ["serum", "ORGANISM_SUBSTANCE", 11, 16], ["serum", "ORGANISM_SUBSTANCE", 60, 65], ["A negative serum", "TEST", 0, 16], ["negative", "OBSERVATION", 2, 10]]], ["The plates were covered and incubated for 2 h at room temperature (21.--25\"C), the fluid was removed, and the wells were rinsed three times with wash buffer (50 mM Tris-HCI, pH 7.2, 150 mM NaCl, I mM EDTA).", [["fluid", "ANATOMY", 83, 88], ["Tris-HCI", "CHEMICAL", 164, 172], ["NaCl", "CHEMICAL", 189, 193], ["Tris-HCI", "CHEMICAL", 164, 172], ["NaCl", "CHEMICAL", 189, 193], ["EDTA", "CHEMICAL", 200, 204], ["fluid", "ORGANISM_SUBSTANCE", 83, 88], ["The plates", "TREATMENT", 0, 10], ["the wells", "TREATMENT", 106, 115], ["wash buffer", "TREATMENT", 145, 156], ["Tris", "TEST", 164, 168], ["HCI", "TEST", 169, 172], ["pH", "TEST", 174, 176], ["plates", "OBSERVATION_MODIFIER", 4, 10], ["fluid", "OBSERVATION", 83, 88]]], ["IBRV anti-g111 monoclonal antibody(G2) --. horseradish peroxidase conjugate (Collins et al., 198411985, 1985) was then added to each well.", [["IBRV", "SIMPLE_CHEMICAL", 0, 4], ["horseradish peroxidase conjugate", "SIMPLE_CHEMICAL", 43, 75], ["IBRV", "PROTEIN", 0, 4], ["anti-g111 monoclonal antibody", "PROTEIN", 5, 34], ["G2", "PROTEIN", 35, 37], ["horseradish", "SPECIES", 43, 54], ["IBRV", "SPECIES", 0, 4], ["IBRV", "TEST", 0, 4], ["monoclonal antibody", "TEST", 15, 34]]], ["The plates were covered, incubated at room temperature for 30 min, and rinsed live times with wash buffer, with tapping dry between washes.", [["The plates", "TREATMENT", 0, 10], ["wash buffer", "TREATMENT", 94, 105], ["plates", "OBSERVATION_MODIFIER", 4, 10]]], ["Finally, 0.1 ml of premixed TMB substrate solutions I and II (KPL) were added to all of the wells, the plates were incubated at 21-25\u00b0C for 20 min, and then 0.5 ml of a stop solution containing 0.01% sodium azide was added to each well, and the color was analyzed by reading the absorbance at 650 nm.", [["I and II", "CHEMICAL", 52, 60], ["KPL", "CHEMICAL", 62, 65], ["sodium azide", "CHEMICAL", 200, 212], ["TMB", "CHEMICAL", 28, 31], ["sodium azide", "CHEMICAL", 200, 212], ["TMB", "SIMPLE_CHEMICAL", 28, 31], ["KPL", "SIMPLE_CHEMICAL", 62, 65], ["sodium azide", "SIMPLE_CHEMICAL", 200, 212], ["premixed TMB substrate solutions I and II (KPL)", "TREATMENT", 19, 66], ["the plates", "TEST", 99, 109], ["a stop solution", "TREATMENT", 167, 182], ["0.01% sodium azide", "TREATMENT", 194, 212]]], ["The absorbance (A) of the blank well (about 0.05) was subtracted from the A readings of the other wells.", [["The absorbance", "TEST", 0, 14], ["absorbance", "OBSERVATION_MODIFIER", 4, 14]]], ["The antigen and monoclonal antibodyconjugate concentrations were adjusted so that the A values of the negative control (fetal calf sera) were from 1.0 to 1.5.", [["fetal calf sera", "ANATOMY", 120, 135], ["calf", "ORGANISM", 126, 130], ["sera", "ORGANISM_SUBSTANCE", 131, 135], ["calf", "SPECIES", 126, 130], ["The antigen", "TEST", 0, 11], ["monoclonal antibodyconjugate concentrations", "TREATMENT", 16, 59], ["fetal calf sera", "TEST", 120, 135]]], ["The A values of the positive control (bovine anti-IBRV sera) were about 0.2 to 0.4.", [["sera", "ANATOMY", 55, 59], ["bovine", "ORGANISM", 38, 44], ["anti-IBRV", "ORGANISM", 45, 54], ["sera", "ORGANISM_SUBSTANCE", 55, 59], ["bovine", "SPECIES", 38, 44], ["bovine", "SPECIES", 38, 44], ["the positive control (bovine anti-IBRV sera", "TREATMENT", 16, 59]]], ["Results on test sera were expressed as S/N values, defined as the A of the test sample (S) divided by the A of the negative control (N).Preliminary control experiments and analyses of gnotohiotic antiseraAnti-IBRV gIII blocking ELISAs carried out on fetal bovine sera, gamma globulin-free fetal bovine sera, and on normal horse, lamb, chick, rabbit, and mouse sera demonstrated that the ratios (S/N) of the A values at 650 nm for these tests samples (S) to the A values at 650 nm of fetal bovine sera (N) were about 0.94 to 1.10 (Table 1) .", [["sera", "ANATOMY", 16, 20], ["sera", "ANATOMY", 263, 267], ["fetal bovine sera", "ANATOMY", 289, 306], ["chick", "ANATOMY", 335, 340], ["sera", "ANATOMY", 360, 364], ["samples", "ANATOMY", 442, 449], ["fetal bovine sera", "ANATOMY", 483, 500], ["gamma globulin", "CHEMICAL", 269, 283], ["sera", "ORGANISM_SUBSTANCE", 16, 20], ["bovine", "ORGANISM", 256, 262], ["sera", "ORGANISM_SUBSTANCE", 263, 267], ["gamma globulin", "GENE_OR_GENE_PRODUCT", 269, 283], ["bovine", "ORGANISM", 295, 301], ["sera", "ORGANISM_SUBSTANCE", 302, 306], ["horse", "ORGANISM", 322, 327], ["lamb", "ORGANISM_SUBDIVISION", 329, 333], ["chick", "ORGANISM", 335, 340], ["rabbit", "ORGANISM", 342, 348], ["mouse", "ORGANISM", 354, 359], ["sera", "ORGANISM_SUBSTANCE", 360, 364], ["bovine", "ORGANISM", 489, 495], ["sera", "ORGANISM_SUBSTANCE", 496, 500], ["gnotohiotic antiseraAnti-IBRV gIII", "PROTEIN", 184, 218], ["gamma globulin", "PROTEIN", 269, 283], ["bovine", "SPECIES", 256, 262], ["bovine", "SPECIES", 295, 301], ["horse", "SPECIES", 322, 327], ["lamb", "SPECIES", 329, 333], ["chick", "SPECIES", 335, 340], ["rabbit", "SPECIES", 342, 348], ["mouse", "SPECIES", 354, 359], ["bovine", "SPECIES", 489, 495], ["bovine", "SPECIES", 256, 262], ["bovine", "SPECIES", 295, 301], ["horse", "SPECIES", 322, 327], ["lamb", "SPECIES", 329, 333], ["chick", "SPECIES", 335, 340], ["rabbit", "SPECIES", 342, 348], ["mouse", "SPECIES", 354, 359], ["bovine", "SPECIES", 489, 495], ["test sera", "TEST", 11, 20], ["the test sample", "TEST", 71, 86], ["Preliminary control experiments", "TEST", 136, 167], ["gnotohiotic antiseraAnti-IBRV gIII blocking ELISAs", "TEST", 184, 234], ["fetal bovine sera", "TEST", 250, 267], ["gamma globulin", "TEST", 269, 283], ["free fetal bovine sera", "TEST", 284, 306], ["mouse sera", "TEST", 354, 364], ["the ratios", "TEST", 383, 393], ["these tests samples", "TEST", 430, 449], ["fetal bovine sera", "TEST", 483, 500]]], ["Similarly, bovine antisera to rotovirus, vesicular1.24Anti-bovine respiratory syncytial virus (NVSL-G) 1.02 Anti-parainfluenza-3 (NVSL-G) and porcine antisera to PRV and parvovirus, exhibited S/N values of 0.98 to 1.40.", [["respiratory syncytial virus", "DISEASE", 66, 93], ["Anti-parainfluenza-3 (NVSL-G", "CHEMICAL", 108, 136], ["bovine", "ORGANISM", 11, 17], ["rotovirus", "GENE_OR_GENE_PRODUCT", 30, 39], ["vesicular1", "GENE_OR_GENE_PRODUCT", 41, 51], ["bovine respiratory syncytial virus", "ORGANISM", 59, 93], ["Anti-parainfluenza-3", "GENE_OR_GENE_PRODUCT", 108, 128], ["NVSL-G", "GENE_OR_GENE_PRODUCT", 130, 136], ["porcine", "ORGANISM", 142, 149], ["PRV", "ORGANISM", 162, 165], ["parvovirus", "ORGANISM", 170, 180], ["bovine", "SPECIES", 11, 17], ["bovine", "SPECIES", 59, 65], ["respiratory syncytial virus", "SPECIES", 66, 93], ["porcine", "SPECIES", 142, 149], ["bovine", "SPECIES", 11, 17], ["bovine respiratory syncytial virus", "SPECIES", 59, 93], ["porcine", "SPECIES", 142, 149], ["PRV", "SPECIES", 162, 165], ["Anti-bovine respiratory syncytial virus", "TEST", 54, 93], ["NVSL", "TEST", 95, 99], ["Anti-parainfluenza", "TEST", 108, 126], ["NVSL", "TEST", 130, 134], ["porcine antisera", "TREATMENT", 142, 158], ["parvovirus", "PROBLEM", 170, 180], ["S/N values", "TEST", 192, 202], ["vesicular1", "ANATOMY", 41, 51], ["respiratory syncytial virus", "OBSERVATION", 66, 93]]], ["Sera supplied by the NVSL-USDA and obtained from gnotobiotic (G) calves immunized with several different viruses had S/N values of 0.86 to I .31. while antisera from calves immunized with IBRV and sera from rabbits infected with IBRV showed SN values of 0.33, 0.35 and 0.26.", [["Sera", "ANATOMY", 0, 4], ["sera", "ANATOMY", 197, 201], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["gnotobiotic (G) calves", "ORGANISM", 49, 71], ["calves", "ORGANISM", 166, 172], ["sera", "ORGANISM_SUBSTANCE", 197, 201], ["rabbits", "ORGANISM", 207, 214], ["calves", "SPECIES", 65, 71], ["calves", "SPECIES", 166, 172], ["rabbits", "SPECIES", 207, 214], ["IBRV", "SPECIES", 188, 192], ["rabbits", "SPECIES", 207, 214], ["IBRV", "SPECIES", 229, 233], ["gnotobiotic (G) calves", "TREATMENT", 49, 71], ["several different viruses", "PROBLEM", 87, 112], ["S/N values", "TEST", 117, 127], ["IBRV", "TREATMENT", 188, 192], ["sera", "TEST", 197, 201], ["IBRV", "TEST", 229, 233], ["SN values", "TEST", 241, 250], ["viruses", "OBSERVATION", 105, 112]]], ["On the basis of these empirical results and the analyses to be described, a tentative decision was made to consider S,:N values > 0.80 as negative and S/N values < 0.80 as positive for IBRV gll I antibodies.", [["gll I antibodies", "GENE_OR_GENE_PRODUCT", 190, 206], ["IBRV", "PROTEIN", 185, 189], ["gll I antibodies", "PROTEIN", 190, 206], ["IBRV", "SPECIES", 185, 189], ["N values", "TEST", 119, 127], ["S/N values", "TEST", 151, 161], ["IBRV gll I antibodies", "PROBLEM", 185, 206]]], ["The caveat is. of course, that sera giving S/N values of 0.75 to 0.85 should be considered borderline (k), requiring repetition of assays or assay of l IBRV glycoproteins g1, gI11, and gIV. with gIV inlInLlni~ation providing the best individual protection (Babiuk et al., 1987 : van Drunen Littel-van den Hurk et al., 1990 and (v) essential glycoprotein gH (Meyer et al., 1991) and other IBRV proteins (e.g. VP8) may contribute to the induction of protective immune responses.", [["sera", "ANATOMY", 31, 35], ["sera", "ORGANISM_SUBSTANCE", 31, 35], ["g1", "GENE_OR_GENE_PRODUCT", 171, 173], ["gI11", "GENE_OR_GENE_PRODUCT", 175, 179], ["gIV", "GENE_OR_GENE_PRODUCT", 185, 188], ["(v) essential glycoprotein gH", "GENE_OR_GENE_PRODUCT", 327, 356], ["IBRV proteins", "GENE_OR_GENE_PRODUCT", 388, 401], ["VP8", "GENE_OR_GENE_PRODUCT", 408, 411], ["IBRV glycoproteins", "PROTEIN", 152, 170], ["g1", "PROTEIN", 171, 173], ["gI11", "PROTEIN", 175, 179], ["gIV", "PROTEIN", 185, 188], ["glycoprotein gH", "PROTEIN", 341, 356], ["IBRV proteins", "PROTEIN", 388, 401], ["VP8", "PROTEIN", 408, 411], ["S/N values", "TEST", 43, 53], ["assays", "TEST", 131, 137], ["l IBRV glycoproteins g1", "TREATMENT", 150, 173], ["gIV inlInLlni~ation", "TREATMENT", 195, 214], ["other IBRV proteins", "TEST", 382, 401], ["caveat", "OBSERVATION", 4, 10]]], ["In the case of the complex herpes viruses, there is neither theoretical nor empirical evidence that deletion of the nonessential gIII(gC) glycoprotein impairs the protective response (Kit, S. and Kit, M., 1991) .Sera from cattle vaccinated with gIII-positive commercial vaccineThe anti-IBRV gII1 blocking ELISA utilizes undiluted test sera.", [["sera", "ANATOMY", 335, 339], ["herpes viruses", "DISEASE", 27, 41], ["gIII", "CHEMICAL", 245, 249], ["herpes viruses", "ORGANISM", 27, 41], ["gIII(gC) glycoprotein", "GENE_OR_GENE_PRODUCT", 129, 150], ["Sera", "ORGANISM_SUBSTANCE", 212, 216], ["cattle", "ORGANISM", 222, 228], ["gIII", "GENE_OR_GENE_PRODUCT", 245, 249], ["anti-IBRV gII1", "GENE_OR_GENE_PRODUCT", 281, 295], ["sera", "ORGANISM_SUBSTANCE", 335, 339], ["nonessential gIII(gC) glycoprotein", "PROTEIN", 116, 150], ["gII1", "PROTEIN", 291, 295], ["cattle", "SPECIES", 222, 228], ["cattle", "SPECIES", 222, 228], ["anti-IBRV", "SPECIES", 281, 290], ["the complex herpes viruses", "PROBLEM", 15, 41], ["Sera", "TEST", 212, 216], ["gIII", "TEST", 245, 249], ["positive commercial vaccine", "TREATMENT", 250, 277], ["The anti-IBRV gII1 blocking ELISA", "TREATMENT", 277, 310], ["undiluted test sera", "TEST", 320, 339], ["complex", "OBSERVATION_MODIFIER", 19, 26], ["herpes viruses", "OBSERVATION", 27, 41]]], ["Hence, time consuming and laborious dilutions of test sera prior to addition to the antigencoated wells is not required.", [["sera", "ANATOMY", 54, 58], ["sera", "ORGANISM_SUBSTANCE", 54, 58], ["test sera", "TEST", 49, 58], ["the antigencoated wells", "TREATMENT", 80, 103]]], ["The gII1 blocking ELISA is specific, as may be seen from the observations that high titered gnotobiotic antisera to heterologous viruses. normal sera from heterologous species, and antisera to the pseudorabies herpesvirus and to bovine herpesvirus-gave negative S,:N values.", [["sera", "ANATOMY", 145, 149], ["pseudorabies herpesvirus", "DISEASE", 197, 221], ["gII1", "GENE_OR_GENE_PRODUCT", 4, 8], ["sera", "ORGANISM_SUBSTANCE", 145, 149], ["pseudorabies herpesvirus", "ORGANISM", 197, 221], ["bovine", "ORGANISM", 229, 235], ["herpesvirus", "ORGANISM", 236, 247], ["gII1", "PROTEIN", 4, 8], ["pseudorabies herpesvirus", "SPECIES", 197, 221], ["bovine", "SPECIES", 229, 235], ["pseudorabies herpesvirus", "SPECIES", 197, 221], ["The gII1 blocking ELISA", "TEST", 0, 23], ["high titered gnotobiotic antisera to heterologous viruses", "PROBLEM", 79, 136], ["heterologous species", "PROBLEM", 155, 175], ["antisera", "TREATMENT", 181, 189], ["the pseudorabies herpesvirus", "PROBLEM", 193, 221], ["bovine herpesvirus", "TEST", 229, 247]]], ["Likewise, sera from animals twice vaccinated with the gIl1 deletion mutant.", [["sera", "ANATOMY", 10, 14], ["sera", "ORGANISM_SUBSTANCE", 10, 14], ["gIl1", "GENE_OR_GENE_PRODUCT", 54, 58], ["gIl1 deletion mutant", "DNA", 54, 74]]], ["IBRV (NG)dltkdlgIII. exhibited negative S/N values.", [["NG", "CHEMICAL", 6, 8], ["IBRV (NG)dltkdlgIII", "GENE_OR_GENE_PRODUCT", 0, 19], ["IBRV (NG)dltkdlgIII", "PROTEIN", 0, 19], ["IBRV (NG)dltkdlgIII", "TREATMENT", 0, 19], ["negative", "OBSERVATION", 31, 39]]], ["The sensitivity of the anti-IBRV gII1 blocking ELISA is demonstrated by the detection of gII1 antibodies in the sera of VN-negative (< l:4) cattle in a herd experiencing an IBRV outbreak, and by the detection of gII1 antibodies in 1 1% 116 calves vaccinated with a gIII-positive commercial vaccine.", [["sera", "ANATOMY", 112, 116], ["gIII", "CHEMICAL", 265, 269], ["anti-IBRV", "ORGANISM", 23, 32], ["gII1", "GENE_OR_GENE_PRODUCT", 33, 37], ["gII1 antibodies", "GENE_OR_GENE_PRODUCT", 89, 104], ["sera", "ORGANISM_SUBSTANCE", 112, 116], ["VN", "GENE_OR_GENE_PRODUCT", 120, 122], ["cattle", "ORGANISM", 140, 146], ["gII1 antibodies", "GENE_OR_GENE_PRODUCT", 212, 227], ["calves", "ORGANISM", 240, 246], ["gIII", "GENE_OR_GENE_PRODUCT", 265, 269], ["anti-IBRV gII1", "PROTEIN", 23, 37], ["gII1 antibodies", "PROTEIN", 89, 104], ["gII1 antibodies", "PROTEIN", 212, 227], ["cattle", "SPECIES", 140, 146], ["calves", "SPECIES", 240, 246], ["anti-IBRV", "SPECIES", 23, 32], ["cattle", "SPECIES", 140, 146], ["IBRV", "SPECIES", 173, 177], ["calves", "SPECIES", 240, 246], ["the anti-IBRV gII1 blocking ELISA", "TEST", 19, 52], ["gII1 antibodies", "TEST", 89, 104], ["the sera", "TEST", 108, 116], ["VN", "TEST", 120, 122], ["an IBRV outbreak", "PROBLEM", 170, 186], ["gII1 antibodies", "TEST", 212, 227]]], ["The one serum from the vaccinate that showed a false negative had a VN titer of I:2 and a ($: ) S/N of 0.83.", [["serum", "ANATOMY", 8, 13], ["serum", "ORGANISM_SUBSTANCE", 8, 13], ["The one serum", "TEST", 0, 13], ["a VN titer", "TEST", 66, 76], ["S/N", "TEST", 96, 99], ["false negative", "OBSERVATION", 47, 61]]], ["Another calf that failed to seroconvert by VN (< l:4) had a strongly positive S/N of 0.48.", [["calf", "ORGANISM", 8, 12], ["VN", "PROTEIN", 43, 45], ["calf", "SPECIES", 8, 12], ["VN", "TEST", 43, 45], ["a strongly positive S/N", "PROBLEM", 58, 81], ["calf", "ANATOMY", 8, 12]]], ["In addition. all the VN-positive (VN = I:2 to 1:128) field sera tested were gIII ELISA-positive, except for one serum with a VN = 2, which showed an S;N of 0.81, close to the borderline cut-off value separating negative from positive sera.Sera from cattle vaccinated with gIII-positive commercial vaccineFinally, the observation that gIII antibodies were detected in sera of animals twice vaccinated with the marker vaccine, IBRV(NG)dltkdlgIII, by 10 to 17 days postvaccination suggest that the gII1 blocking ELISA test is sufficiently sensitive to detect those field strain infections of vaccinated cattle which have the potential to reactivate from latency and spread in a herd.", [["sera", "ANATOMY", 59, 63], ["serum", "ANATOMY", 112, 117], ["sera", "ANATOMY", 234, 238], ["sera", "ANATOMY", 367, 371], ["NG", "CHEMICAL", 430, 432], ["infections", "DISEASE", 575, 585], ["VN", "GENE_OR_GENE_PRODUCT", 21, 23], ["sera", "ORGANISM_SUBSTANCE", 59, 63], ["gIII", "GENE_OR_GENE_PRODUCT", 76, 80], ["serum", "ORGANISM_SUBSTANCE", 112, 117], ["sera", "ORGANISM_SUBSTANCE", 234, 238], ["Sera", "ORGANISM_SUBSTANCE", 239, 243], ["cattle", "ORGANISM", 249, 255], ["gIII", "GENE_OR_GENE_PRODUCT", 272, 276], ["gIII antibodies", "GENE_OR_GENE_PRODUCT", 334, 349], ["sera", "ORGANISM_SUBSTANCE", 367, 371], ["gII1", "GENE_OR_GENE_PRODUCT", 495, 499], ["cattle", "ORGANISM", 600, 606], ["VN", "PROTEIN", 21, 23], ["gIII antibodies", "PROTEIN", 334, 349], ["gII1", "PROTEIN", 495, 499], ["cattle", "SPECIES", 249, 255], ["cattle", "SPECIES", 600, 606], ["cattle", "SPECIES", 249, 255], ["IBRV", "SPECIES", 425, 429], ["cattle", "SPECIES", 600, 606], ["all the VN", "TEST", 13, 23], ["VN", "TEST", 34, 36], ["field sera", "TEST", 53, 63], ["gIII ELISA", "TEST", 76, 86], ["one serum", "TEST", 108, 117], ["a VN", "TEST", 123, 127], ["an S", "TEST", 146, 150], ["N", "TEST", 151, 152], ["Sera", "TEST", 239, 243], ["gIII", "TEST", 272, 276], ["gIII antibodies", "TEST", 334, 349], ["the marker vaccine", "TREATMENT", 405, 423], ["IBRV(NG)dltkdlgIII", "TREATMENT", 425, 443], ["the gII1 blocking ELISA test", "TEST", 491, 519], ["vaccinated cattle", "PROBLEM", 589, 606], ["latency", "PROBLEM", 651, 658], ["positive", "OBSERVATION", 24, 32]]], ["The development of the gene-deleted IBRV marker vaccine and differential diagnostic test kit may facilitate the implementation of IBRV control/eradication programs analogous to those already undertaken for Aujeszky's disease.", [["Aujeszky's disease", "DISEASE", 206, 224], ["IBRV", "GENE_OR_GENE_PRODUCT", 36, 40], ["Aujeszky", "ORGANISM", 206, 214], ["Aujeszky", "SPECIES", 206, 214], ["IBRV", "SPECIES", 130, 134], ["Aujeszky", "SPECIES", 206, 214], ["the gene-deleted IBRV marker vaccine", "TREATMENT", 19, 55], ["differential diagnostic test kit", "TEST", 60, 92], ["IBRV control", "TREATMENT", 130, 142], ["eradication programs", "TREATMENT", 143, 163], ["Aujeszky's disease", "PROBLEM", 206, 224]]]], "65648f466638ba2c4b63d49a1c46e834719890a5": [["IntroductionThe genus Pneumocystis contains highly diversified and opportunistic fungal species that cause severe pneumonia in mammals with a deficient immune system.", [["Pneumocystis", "DISEASE", 22, 34], ["pneumonia", "DISEASE", 114, 123], ["Pneumocystis", "ORGANISM", 22, 34], ["The genus Pneumocystis", "PROBLEM", 12, 34], ["opportunistic fungal species", "PROBLEM", 67, 95], ["severe pneumonia in mammals", "PROBLEM", 107, 134], ["a deficient immune system", "PROBLEM", 140, 165], ["genus Pneumocystis", "OBSERVATION", 16, 34], ["highly", "OBSERVATION_MODIFIER", 44, 50], ["diversified", "OBSERVATION_MODIFIER", 51, 62], ["opportunistic", "OBSERVATION_MODIFIER", 67, 80], ["fungal species", "OBSERVATION", 81, 95], ["severe", "OBSERVATION_MODIFIER", 107, 113], ["pneumonia", "OBSERVATION", 114, 123], ["deficient immune system", "OBSERVATION", 142, 165]]], ["1 In the veterinary literature, there are many published cases of confirmed canine pneumocystosis-most of which described cases of young to middle-age dogs with suspected immunodeficiency, with the Miniature Dachshund, and the Cavalier King Charles Spaniel (CKCS) breeds most commonly reported.", [["canine pneumocystosis", "DISEASE", 76, 97], ["immunodeficiency", "DISEASE", 171, 187], ["canine", "ORGANISM", 76, 82], ["dogs", "ORGANISM", 151, 155], ["canine", "SPECIES", 76, 82], ["dogs", "SPECIES", 151, 155], ["canine", "SPECIES", 76, 82], ["canine pneumocystosis", "PROBLEM", 76, 97], ["suspected immunodeficiency", "PROBLEM", 161, 187], ["canine", "OBSERVATION_MODIFIER", 76, 82], ["pneumocystosis", "OBSERVATION", 83, 97], ["immunodeficiency", "OBSERVATION", 171, 187]]], ["[1] [2] [3] [4] [5] [6] [7] [8] Concurrent infection with other pathogens has been reported in only a few cases when concurrent Demodex canis 3, 5, 7 and canine distemper virus (CDV) 3 infections were demonstrated.", [["infection", "DISEASE", 43, 52], ["Demodex canis", "DISEASE", 128, 141], ["canine distemper", "DISEASE", 154, 170], ["infections", "DISEASE", 185, 195], ["[1] [2] [3] [4] [5] [6] [7] [8]", "SIMPLE_CHEMICAL", 0, 31], ["Demodex canis 3", "ORGANISM", 128, 143], ["5", "ORGANISM", 145, 146], ["canine distemper virus", "ORGANISM", 154, 176], ["CDV) 3", "ORGANISM", 178, 184], ["Demodex canis", "SPECIES", 128, 141], ["canine distemper virus", "SPECIES", 154, 176], ["Demodex canis", "SPECIES", 128, 141], ["canine distemper virus", "SPECIES", 154, 176], ["CDV", "SPECIES", 178, 181], ["Concurrent infection", "PROBLEM", 32, 52], ["other pathogens", "PROBLEM", 58, 73], ["Demodex canis", "TEST", 128, 141], ["canine distemper virus (CDV) 3 infections", "PROBLEM", 154, 195], ["infection", "OBSERVATION", 43, 52], ["distemper virus", "OBSERVATION", 161, 176]]], ["In most of the previously reported veterinary cases, in vivo diagnosis of Pneumocystis spp. pneumonia (PP) was achieved by direct identification of the microorganism by cytological examination of bronchoalveolar lavage (BAL) samples, trans-tracheal aspirates, or transthoracic lung aspirates.", [["bronchoalveolar lavage (BAL) samples", "ANATOMY", 196, 232], ["tracheal aspirates", "ANATOMY", 240, 258], ["transthoracic lung aspirates", "ANATOMY", 263, 291], ["Pneumocystis spp", "DISEASE", 74, 90], ["pneumonia", "DISEASE", 92, 101], ["Pneumocystis spp", "ORGANISM", 74, 90], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 196, 218], ["tracheal aspirates", "MULTI-TISSUE_STRUCTURE", 240, 258], ["lung aspirates", "MULTI-TISSUE_STRUCTURE", 277, 291], ["Pneumocystis spp", "PROBLEM", 74, 90], ["pneumonia", "PROBLEM", 92, 101], ["the microorganism", "PROBLEM", 148, 165], ["cytological examination", "TEST", 169, 192], ["bronchoalveolar lavage", "TEST", 196, 218], ["BAL) samples", "TEST", 220, 232], ["trans-tracheal aspirates", "TEST", 234, 258], ["transthoracic lung aspirates", "TEST", 263, 291], ["Pneumocystis spp", "OBSERVATION", 74, 90], ["bronchoalveolar lavage", "OBSERVATION", 196, 218], ["tracheal", "ANATOMY", 240, 248], ["aspirates", "OBSERVATION", 249, 258], ["lung", "ANATOMY", 277, 281], ["aspirates", "OBSERVATION", 282, 291]]], ["2 However, using this technique, the diagnosis can be missed due to failure on detection of the lung pathogen.", [["lung", "ANATOMY", 96, 100], ["lung", "ORGAN", 96, 100], ["this technique", "TREATMENT", 17, 31], ["failure", "PROBLEM", 68, 75], ["the lung pathogen", "PROBLEM", 92, 109], ["lung", "ANATOMY", 96, 100], ["pathogen", "OBSERVATION", 101, 109]]], ["2, 4, 6, 9 In human medicine, several studies have demonstrated that polymerase chain reaction (PCR)-based methods increase the sensitivity of detection of the organism compared to its direct identification on lung samples.", [["lung samples", "ANATOMY", 210, 222], ["human", "ORGANISM", 14, 19], ["lung samples", "CANCER", 210, 222], ["human", "SPECIES", 14, 19], ["human", "SPECIES", 14, 19], ["several studies", "TEST", 30, 45], ["polymerase chain reaction", "PROBLEM", 69, 94], ["PCR)", "TEST", 96, 100], ["the organism", "PROBLEM", 156, 168], ["lung samples", "TEST", 210, 222], ["lung", "ANATOMY", 210, 214]]], ["10, 11 Indeed, real-time PCR has been recently recommended for PP diagnosis by a European panel of experts.", [["a European panel", "TEST", 79, 95]]], ["12 The aim of this report was to describe the first case of Pneumocystis carinii f. sp. canis infection in a suspected immunocompromised CKCS, with four concurrent pulmonary infective agents and one extrapulmonary infectious agent.", [["CKCS", "ANATOMY", 137, 141], ["pulmonary", "ANATOMY", 164, 173], ["Pneumocystis carinii f. sp", "DISEASE", 60, 86], ["canis infection", "DISEASE", 88, 103], ["CKCS", "DISEASE", 137, 141], ["pulmonary infective agents", "DISEASE", 164, 190], ["Pneumocystis carinii", "ORGANISM", 60, 80], ["canis", "ORGANISM", 88, 93], ["CKCS", "CANCER", 137, 141], ["Pneumocystis carinii", "SPECIES", 60, 80], ["canis", "SPECIES", 88, 93], ["Pneumocystis carinii", "SPECIES", 60, 80], ["canis", "SPECIES", 88, 93], ["Pneumocystis carinii f.", "PROBLEM", 60, 83], ["canis infection", "PROBLEM", 88, 103], ["a suspected immunocompromised CKCS", "PROBLEM", 107, 141], ["pulmonary infective agents", "TREATMENT", 164, 190], ["one extrapulmonary infectious agent", "PROBLEM", 195, 230], ["Pneumocystis carinii", "OBSERVATION", 60, 80], ["infection", "OBSERVATION", 94, 103], ["pulmonary", "ANATOMY", 164, 173], ["infective", "OBSERVATION", 174, 183], ["extrapulmonary", "ANATOMY", 199, 213], ["infectious", "OBSERVATION", 214, 224]]], ["In this case, an in vivo identification of Pneumocystis spp. was achieved by PCR testing of BAL fluid, in which no Pneumocystis cysts had been identified with cytological examination.Case reportA 7-month-old CKCS female, with a history of chronic coughing, was referred to the \"San Marco Veterinary Clinic\" (Padova, Italy) for further investigations.", [["BAL fluid", "ANATOMY", 92, 101], ["cysts", "ANATOMY", 128, 133], ["Pneumocystis spp", "DISEASE", 43, 59], ["Pneumocystis cysts", "DISEASE", 115, 133], ["chronic coughing", "DISEASE", 239, 255], ["Pneumocystis spp", "ORGANISM", 43, 59], ["BAL fluid", "ORGANISM_SUBSTANCE", 92, 101], ["Pneumocystis", "ORGANISM", 115, 127], ["cysts", "PATHOLOGICAL_FORMATION", 128, 133], ["CKCS", "ORGANISM", 208, 212], ["female", "ORGANISM", 213, 219], ["Pneumocystis spp", "SPECIES", 43, 59], ["Pneumocystis spp", "PROBLEM", 43, 59], ["PCR testing", "TEST", 77, 88], ["BAL fluid", "TEST", 92, 101], ["Pneumocystis cysts", "PROBLEM", 115, 133], ["cytological examination", "TEST", 159, 182], ["chronic coughing", "PROBLEM", 239, 255], ["further investigations", "TEST", 327, 349], ["Pneumocystis spp", "OBSERVATION", 43, 59], ["BAL fluid", "OBSERVATION", 92, 101], ["no", "UNCERTAINTY", 112, 114], ["Pneumocystis", "OBSERVATION_MODIFIER", 115, 127], ["cysts", "OBSERVATION", 128, 133], ["chronic", "OBSERVATION_MODIFIER", 239, 246], ["coughing", "OBSERVATION", 247, 255]]], ["The dog was not vaccinated and had not received any heartworm prophylaxis in the previous 3 months.", [["dog", "ORGANISM", 4, 7], ["heartworm", "ORGANISM", 52, 61], ["dog", "SPECIES", 4, 7], ["dog", "SPECIES", 4, 7], ["any heartworm prophylaxis", "TREATMENT", 48, 73]]], ["Consecutive antibiotic treatments with appropriate doses of doxycycline, metronidazole-spiramycin, and finally, a 10-day course of amoxicillin-clavulanic acid all had all failed to resolve or even improve clinical signs.", [["doxycycline", "CHEMICAL", 60, 71], ["metronidazole", "CHEMICAL", 73, 86], ["spiramycin", "CHEMICAL", 87, 97], ["amoxicillin-clavulanic acid", "CHEMICAL", 131, 158], ["doxycycline", "CHEMICAL", 60, 71], ["metronidazole", "CHEMICAL", 73, 86], ["spiramycin", "CHEMICAL", 87, 97], ["amoxicillin-clavulanic acid", "CHEMICAL", 131, 158], ["doxycycline", "SIMPLE_CHEMICAL", 60, 71], ["metronidazole", "SIMPLE_CHEMICAL", 73, 86], ["spiramycin", "SIMPLE_CHEMICAL", 87, 97], ["amoxicillin-clavulanic acid", "SIMPLE_CHEMICAL", 131, 158], ["Consecutive antibiotic treatments", "TREATMENT", 0, 33], ["doxycycline", "TREATMENT", 60, 71], ["metronidazole", "TREATMENT", 73, 86], ["spiramycin", "TREATMENT", 87, 97], ["amoxicillin", "TREATMENT", 131, 142], ["clavulanic acid", "TREATMENT", 143, 158]]], ["Antibiotic treatment was discontinued 4 days before presentation.", [["Antibiotic treatment", "TREATMENT", 0, 20]]], ["Two previous fecal Baermann's tests were negative for Angiostrongylus vasorum.", [["Angiostrongylus vasorum", "DISEASE", 54, 77], ["Angiostrongylus vasorum", "ORGANISM", 54, 77], ["Angiostrongylus vasorum", "SPECIES", 54, 77], ["Angiostrongylus vasorum", "SPECIES", 54, 77], ["Two previous fecal Baermann's tests", "TEST", 0, 35], ["Angiostrongylus vasorum", "PROBLEM", 54, 77], ["fecal", "ANATOMY", 13, 18], ["negative for", "UNCERTAINTY", 41, 53], ["Angiostrongylus vasorum", "OBSERVATION", 54, 77]]], ["PCR testing of a nasal swab for CDV, adenovirus 2 (CAV-2), herpesvirus 1, influenza virus, parainfluenza virus (CPiV), and respiratory coronavirus was also negative.", [["nasal swab", "ANATOMY", 17, 27], ["influenza virus", "DISEASE", 74, 89], ["parainfluenza virus", "DISEASE", 91, 110], ["respiratory coronavirus", "DISEASE", 123, 146], ["CDV", "ORGANISM", 32, 35], ["adenovirus 2", "ORGANISM", 37, 49], ["CAV-2", "ORGANISM", 51, 56], ["herpesvirus 1", "ORGANISM", 59, 72], ["influenza virus", "ORGANISM", 74, 89], ["parainfluenza virus", "ORGANISM", 91, 110], ["CPiV", "ORGANISM", 112, 116], ["respiratory coronavirus", "ORGANISM", 123, 146], ["CAV-2", "SPECIES", 51, 56], ["influenza virus, parainfluenza virus", "SPECIES", 74, 110], ["CDV", "SPECIES", 32, 35], ["CAV-2", "SPECIES", 51, 56], ["herpesvirus 1", "SPECIES", 59, 72], ["parainfluenza virus", "SPECIES", 91, 110], ["CPiV", "SPECIES", 112, 116], ["respiratory coronavirus", "SPECIES", 123, 146], ["PCR testing", "TEST", 0, 11], ["a nasal swab", "TEST", 15, 27], ["CDV", "TEST", 32, 35], ["adenovirus", "TEST", 37, 47], ["CAV", "TEST", 51, 54], ["herpesvirus", "PROBLEM", 59, 70], ["influenza virus", "PROBLEM", 74, 89], ["parainfluenza virus", "PROBLEM", 91, 110], ["respiratory coronavirus", "PROBLEM", 123, 146], ["nasal", "ANATOMY", 17, 22], ["parainfluenza virus", "OBSERVATION", 91, 110], ["respiratory coronavirus", "ANATOMY", 123, 146]]], ["On presentation, the dog was bright and alert, mildly tachypneic (40 r/min) with a bilateral mucous nasal discharge.", [["mucous nasal", "ANATOMY", 93, 105], ["dog", "ORGANISM", 21, 24], ["mucous nasal", "ORGANISM_SUBDIVISION", 93, 105], ["dog", "SPECIES", 21, 24], ["mildly tachypneic", "PROBLEM", 47, 64], ["a bilateral mucous nasal discharge", "PROBLEM", 81, 115], ["bilateral", "ANATOMY_MODIFIER", 83, 92], ["mucous nasal", "ANATOMY", 93, 105], ["discharge", "OBSERVATION", 106, 115]]], ["The remaining physical examination was normal.", [["The remaining physical examination", "TEST", 0, 34], ["normal", "OBSERVATION", 39, 45]]], ["A blood sample was taken for a complete blood count, including blood smear examination, serum biochemistry, and serum electrophoresis, and for a coagulation profile.", [["blood sample", "ANATOMY", 2, 14], ["blood", "ANATOMY", 40, 45], ["blood", "ANATOMY", 63, 68], ["serum", "ANATOMY", 88, 93], ["serum", "ANATOMY", 112, 117], ["blood", "ORGANISM_SUBSTANCE", 2, 7], ["blood", "ORGANISM_SUBSTANCE", 40, 45], ["blood", "ORGANISM_SUBSTANCE", 63, 68], ["serum", "ORGANISM_SUBSTANCE", 88, 93], ["serum", "ORGANISM_SUBSTANCE", 112, 117], ["A blood sample", "TEST", 0, 14], ["a complete blood count", "TEST", 29, 51], ["blood smear examination", "TEST", 63, 86], ["serum biochemistry", "TEST", 88, 106], ["serum electrophoresis", "TEST", 112, 133], ["a coagulation profile", "TEST", 143, 164]]], ["Urinalysis was performed on a urine sample obtained via cystocentesis.", [["urine sample", "ANATOMY", 30, 42], ["urine", "ORGANISM_SUBSTANCE", 30, 35], ["Urinalysis", "TEST", 0, 10], ["a urine sample", "TEST", 28, 42], ["cystocentesis", "TREATMENT", 56, 69]]], ["Right lateral and dorso-ventral thoracic radiographs were also taken.", [["Right lateral", "ANATOMY", 0, 13], ["dorso-ventral thoracic", "ANATOMY", 18, 40], ["lateral", "MULTI-TISSUE_STRUCTURE", 6, 13], ["Right lateral and dorso-ventral thoracic radiographs", "TEST", 0, 52], ["lateral", "ANATOMY_MODIFIER", 6, 13], ["dorso-ventral", "ANATOMY_MODIFIER", 18, 31], ["thoracic", "ANATOMY", 32, 40]]], ["Clinicopathological abnormal findings included a mild nonregenerative, normocytic normochromic anemia (5.27 \u00d7 10 12 /L; reference interval, 5.81-7.12), leukocytosis (35.8 \u00d7 10 9 /L; reference interval, 8.33-14.79) with neutrophilia (24.3 \u00d7 10 9 /L; reference interval, 4.0-8.1), lymphocytosis (10.0 \u00d7 10 9 /L; reference interval 2.1-4.9), and monocytosis (1.0 \u00d7 10 9 /L; reference interval, 2.9-7.0).", [["monocytosis", "ANATOMY", 343, 354], ["anemia", "DISEASE", 95, 101], ["leukocytosis", "DISEASE", 152, 164], ["neutrophilia", "DISEASE", 219, 231], ["lymphocytosis", "DISEASE", 279, 292], ["monocytosis", "DISEASE", 343, 354], ["Clinicopathological abnormal findings", "PROBLEM", 0, 37], ["a mild nonregenerative, normocytic normochromic anemia", "PROBLEM", 47, 101], ["reference interval", "TEST", 120, 138], ["leukocytosis", "TEST", 152, 164], ["reference interval", "TEST", 182, 200], ["neutrophilia", "TEST", 219, 231], ["interval", "TEST", 259, 267], ["lymphocytosis", "TEST", 279, 292], ["interval", "TEST", 320, 328], ["monocytosis", "TEST", 343, 354], ["reference interval", "TEST", 371, 389], ["mild", "OBSERVATION_MODIFIER", 49, 53], ["nonregenerative", "OBSERVATION_MODIFIER", 54, 69], ["normocytic", "OBSERVATION_MODIFIER", 71, 81], ["normochromic anemia", "OBSERVATION", 82, 101], ["leukocytosis", "OBSERVATION", 152, 164], ["neutrophilia", "OBSERVATION", 219, 231], ["lymphocytosis", "OBSERVATION", 279, 292], ["monocytosis", "OBSERVATION", 343, 354]]], ["On blood smear examination, there were activated lymphocytes and toxic neutrophils.", [["blood", "ANATOMY", 3, 8], ["lymphocytes", "ANATOMY", 49, 60], ["neutrophils", "ANATOMY", 71, 82], ["blood", "ORGANISM_SUBSTANCE", 3, 8], ["lymphocytes", "CELL", 49, 60], ["neutrophils", "CELL", 71, 82], ["activated lymphocytes", "CELL_TYPE", 39, 60], ["toxic neutrophils", "CELL_TYPE", 65, 82], ["blood smear examination", "TEST", 3, 26], ["activated lymphocytes", "PROBLEM", 39, 60], ["toxic neutrophils", "PROBLEM", 65, 82], ["activated lymphocytes", "OBSERVATION", 39, 60], ["toxic neutrophils", "OBSERVATION", 65, 82]]], ["Serum biochemical profiles showed an increase in serum C-reactive protein (6.9 mg/L; reference interval, 0.1-0.6), a mild hypoalbuminemia (27 g/L; reference interval, 29-33), and a mild hypoglobulinemia (21 g/L; reference interval, 24-32).", [["Serum", "ANATOMY", 0, 5], ["serum", "ANATOMY", 49, 54], ["hypoalbuminemia", "DISEASE", 122, 137], ["hypoglobulinemia", "DISEASE", 186, 202], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["serum", "ORGANISM_SUBSTANCE", 49, 54], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 55, 73], ["serum C-reactive protein", "PROTEIN", 49, 73], ["Serum biochemical profiles", "TEST", 0, 26], ["an increase", "PROBLEM", 34, 45], ["serum C", "TEST", 49, 56], ["reactive protein", "TEST", 57, 73], ["interval", "TEST", 95, 103], ["a mild hypoalbuminemia", "PROBLEM", 115, 137], ["a mild hypoglobulinemia", "PROBLEM", 179, 202], ["increase", "OBSERVATION_MODIFIER", 37, 45], ["mild", "OBSERVATION_MODIFIER", 117, 121], ["hypoalbuminemia", "OBSERVATION", 122, 137], ["mild", "OBSERVATION_MODIFIER", 181, 185], ["hypoglobulinemia", "OBSERVATION", 186, 202]]], ["Serum immunoglobulin fraction quantification showed a decreased immunoglobulin G (IgG) concentration (0.58 g/L; reference interval 0.9-3.72), while immunoglobulin M (IgM) and immunoglobulin A (IgA) concentrations were at the lower limit of the reference intervals (0.79 g/L; reference interval, 0.76-1.8 and 0.018 g/L; reference interval, 0.001-0.09; respectively).", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 6, 20], ["immunoglobulin G", "GENE_OR_GENE_PRODUCT", 64, 80], ["IgG", "GENE_OR_GENE_PRODUCT", 82, 85], ["immunoglobulin M", "GENE_OR_GENE_PRODUCT", 148, 164], ["IgM", "GENE_OR_GENE_PRODUCT", 166, 169], ["immunoglobulin A", "SIMPLE_CHEMICAL", 175, 191], ["IgA", "GENE_OR_GENE_PRODUCT", 193, 196], ["immunoglobulin G", "PROTEIN", 64, 80], ["IgG", "PROTEIN", 82, 85], ["immunoglobulin M", "PROTEIN", 148, 164], ["IgM", "PROTEIN", 166, 169], ["immunoglobulin A", "PROTEIN", 175, 191], ["IgA", "PROTEIN", 193, 196], ["Serum immunoglobulin fraction quantification", "TEST", 0, 44], ["a decreased immunoglobulin G", "TREATMENT", 52, 80], ["IgG", "TEST", 82, 85], ["concentration", "TEST", 87, 100], ["interval", "TEST", 122, 130], ["immunoglobulin M", "TEST", 148, 164], ["IgM", "TEST", 166, 169], ["immunoglobulin A (IgA) concentrations", "TEST", 175, 212], ["interval", "TEST", 285, 293], ["lower limit", "OBSERVATION_MODIFIER", 225, 236]]], ["Serum globulin quantification was in agreement with those detected by micro-capillary electrophoresis diagram (Table 1 and Figure 1 ).", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["globulin", "GENE_OR_GENE_PRODUCT", 6, 14], ["Serum globulin quantification", "TEST", 0, 29], ["micro-capillary electrophoresis diagram", "TEST", 70, 109]]], ["Rod-shaped bacteria and pyuria were detected with urine sediment examination and therefore urine culture was performed.", [["urine", "ANATOMY", 50, 55], ["urine", "ANATOMY", 91, 96], ["pyuria", "DISEASE", 24, 30], ["pyuria", "ORGANISM_SUBSTANCE", 24, 30], ["urine", "ORGANISM_SUBSTANCE", 50, 55], ["urine", "ORGANISM_SUBSTANCE", 91, 96], ["Rod-shaped bacteria", "PROBLEM", 0, 19], ["pyuria", "PROBLEM", 24, 30], ["urine sediment examination", "TEST", 50, 76], ["urine culture", "TEST", 91, 104], ["shaped", "OBSERVATION_MODIFIER", 4, 10], ["bacteria", "OBSERVATION", 11, 19], ["pyuria", "OBSERVATION", 24, 30]]], ["All the remaining clinicopathological tests were normal.", [["All the remaining clinicopathological tests", "TEST", 0, 43], ["normal", "OBSERVATION", 49, 55]]], ["The radiographs of the thorax showed a mild diffuse bronchial pattern (Figure 2 Rhinoscopy, bronchoscopy, and BAL were performed to further elucidate the clinical signs.", [["thorax", "ANATOMY", 23, 29], ["bronchial", "ANATOMY", 52, 61], ["thorax", "ORGAN", 23, 29], ["The radiographs of the thorax", "TEST", 0, 29], ["a mild diffuse bronchial pattern", "PROBLEM", 37, 69], ["Figure 2 Rhinoscopy", "TEST", 71, 90], ["bronchoscopy", "TEST", 92, 104], ["BAL", "TEST", 110, 113], ["the clinical signs", "TEST", 150, 168], ["thorax", "ANATOMY", 23, 29], ["mild", "OBSERVATION_MODIFIER", 39, 43], ["diffuse", "OBSERVATION_MODIFIER", 44, 51], ["bronchial", "ANATOMY", 52, 61]]], ["The dog was pre-medicated with butorphanol (0.2 mg/kg, IM) and dexmedetomidine (0.002 mg/kg, IM), induced with propofol (2 mg/kg) and maintained using a propofol infusion (0.1-0.4 mg/kg/ min).", [["butorphanol", "CHEMICAL", 31, 42], ["dexmedetomidine", "CHEMICAL", 63, 78], ["propofol", "CHEMICAL", 111, 119], ["propofol", "CHEMICAL", 153, 161], ["butorphanol", "CHEMICAL", 31, 42], ["dexmedetomidine", "CHEMICAL", 63, 78], ["propofol", "CHEMICAL", 111, 119], ["propofol", "CHEMICAL", 153, 161], ["dog", "ORGANISM", 4, 7], ["butorphanol", "SIMPLE_CHEMICAL", 31, 42], ["dexmedetomidine", "SIMPLE_CHEMICAL", 63, 78], ["propofol", "SIMPLE_CHEMICAL", 111, 119], ["propofol", "SIMPLE_CHEMICAL", 153, 161], ["dog", "SPECIES", 4, 7], ["dog", "SPECIES", 4, 7], ["butorphanol", "TREATMENT", 31, 42], ["dexmedetomidine", "TREATMENT", 63, 78], ["propofol", "TREATMENT", 111, 119], ["a propofol infusion", "TREATMENT", 151, 170]]], ["Flow by 100% oxygen delivery was provided during the entire procedure until the dog was fully recovered.", [["oxygen", "CHEMICAL", 13, 19], ["oxygen", "CHEMICAL", 13, 19], ["oxygen", "SIMPLE_CHEMICAL", 13, 19], ["dog", "ORGANISM", 80, 83], ["dog", "SPECIES", 80, 83], ["Flow", "TEST", 0, 4], ["100% oxygen delivery", "TREATMENT", 8, 28], ["the entire procedure", "TREATMENT", 49, 69]]], ["A small flexible fiberoptic bronchoscope was used.", [["A small flexible fiberoptic bronchoscope", "TREATMENT", 0, 40], ["small", "OBSERVATION_MODIFIER", 2, 7], ["flexible", "OBSERVATION_MODIFIER", 8, 16], ["fiberoptic bronchoscope", "OBSERVATION", 17, 40]]], ["Pulse oximetry, electrocardiography (ECG), and blood pressure were monitored throughout the procedure.", [["blood", "ANATOMY", 47, 52], ["blood", "ORGANISM_SUBSTANCE", 47, 52], ["Pulse oximetry", "TEST", 0, 14], ["electrocardiography", "TEST", 16, 35], ["ECG", "TEST", 37, 40], ["blood pressure", "TEST", 47, 61], ["the procedure", "TREATMENT", 88, 101]]], ["A diffuse, productive bronchopathy and a non-specific mucous-productive rhinopathy were identified.", [["mucous", "ANATOMY", 54, 60], ["bronchopathy", "DISEASE", 22, 34], ["rhinopathy", "DISEASE", 72, 82], ["bronchopathy", "CANCER", 22, 34], ["mucous", "PATHOLOGICAL_FORMATION", 54, 60], ["rhinopathy", "CANCER", 72, 82], ["A diffuse, productive bronchopathy", "PROBLEM", 0, 34], ["a non-specific mucous-productive rhinopathy", "PROBLEM", 39, 82], ["diffuse", "OBSERVATION_MODIFIER", 2, 9], ["productive", "OBSERVATION_MODIFIER", 11, 21], ["bronchopathy", "OBSERVATION", 22, 34], ["non-specific", "OBSERVATION_MODIFIER", 41, 53], ["mucous", "OBSERVATION_MODIFIER", 54, 60], ["productive", "OBSERVATION_MODIFIER", 61, 71], ["rhinopathy", "OBSERVATION", 72, 82]]], ["BAL was performed by instilling two aliquots of 5 mL of warmed sterile 0.9% saline by syringe, followed by approximately 5 mL of air to clear the fluid from the endoscope channel before the saline was aspirated.", [["BAL", "ANATOMY", 0, 3], ["fluid", "ANATOMY", 146, 151], ["BAL", "ORGANISM_SUBSTANCE", 0, 3], ["saline", "SIMPLE_CHEMICAL", 76, 82], ["saline", "SIMPLE_CHEMICAL", 190, 196], ["BAL", "TEST", 0, 3], ["warmed sterile 0.9% saline", "TREATMENT", 56, 82], ["the endoscope channel", "TREATMENT", 157, 178], ["the saline", "TREATMENT", 186, 196], ["fluid", "OBSERVATION", 146, 151]]], ["The BAL sample was immediately submitted for cytological analysis and bacterial culture.Case reportPolymerase chain reaction testing for CDV, CAV-2, CPiV, Angiostrongylus vasorum, Bordetella bronchiseptica, Mycoplasma spp., and Pneumocystis spp. was also performed.", [["BAL sample", "ANATOMY", 4, 14], ["Angiostrongylus vasorum", "DISEASE", 155, 178], ["Bordetella bronchiseptica", "DISEASE", 180, 205], ["Mycoplasma spp.", "DISEASE", 207, 222], ["Pneumocystis spp", "DISEASE", 228, 244], ["BAL sample", "CANCER", 4, 14], ["CDV", "ORGANISM", 137, 140], ["CAV-2", "ORGANISM", 142, 147], ["CPiV", "ORGANISM", 149, 153], ["Angiostrongylus vasorum", "ORGANISM", 155, 178], ["Bordetella bronchiseptica", "ORGANISM", 180, 205], ["Mycoplasma spp.", "ORGANISM", 207, 222], ["Pneumocystis spp", "ORGANISM", 228, 244], ["Angiostrongylus vasorum", "SPECIES", 155, 178], ["Bordetella bronchiseptica", "SPECIES", 180, 205], ["Mycoplasma spp.", "SPECIES", 207, 222], ["Pneumocystis spp", "SPECIES", 228, 244], ["CDV", "SPECIES", 137, 140], ["CAV-2", "SPECIES", 142, 147], ["CPiV", "SPECIES", 149, 153], ["Angiostrongylus vasorum", "SPECIES", 155, 178], ["Bordetella bronchiseptica", "SPECIES", 180, 205], ["Mycoplasma spp.", "SPECIES", 207, 222], ["Pneumocystis spp", "SPECIES", 228, 244], ["The BAL sample", "TEST", 0, 14], ["cytological analysis", "TEST", 45, 65], ["bacterial culture", "TEST", 70, 87], ["Case reportPolymerase chain reaction testing", "TEST", 88, 132], ["CDV", "PROBLEM", 137, 140], ["CAV", "TEST", 142, 145], ["CPiV", "PROBLEM", 149, 153], ["Angiostrongylus vasorum", "PROBLEM", 155, 178], ["Bordetella bronchiseptica", "PROBLEM", 180, 205], ["Mycoplasma spp.", "PROBLEM", 207, 222], ["Pneumocystis spp", "PROBLEM", 228, 244], ["BAL", "ANATOMY", 4, 7], ["Angiostrongylus vasorum", "ANATOMY", 155, 178], ["Mycoplasma spp.", "OBSERVATION", 207, 222], ["Pneumocystis spp", "OBSERVATION", 228, 244]]], ["To investigate the presence of Pneumocystis spp., a portion of the mitochondrial small subunit rRNA gene (mtSSU rRNA gene) was amplified and sequenced by nested PCR with previously reported primers and protocol.", [["mitochondrial", "ANATOMY", 67, 80], ["Pneumocystis spp.", "DISEASE", 31, 48], ["Pneumocystis spp.", "ORGANISM", 31, 48], ["mitochondrial", "CELLULAR_COMPONENT", 67, 80], ["mtSSU rRNA", "GENE_OR_GENE_PRODUCT", 106, 116], ["mitochondrial small subunit rRNA gene", "DNA", 67, 104], ["mtSSU rRNA gene", "DNA", 106, 121], ["Pneumocystis spp.", "SPECIES", 31, 48], ["Pneumocystis spp.", "SPECIES", 31, 48], ["Pneumocystis spp.", "PROBLEM", 31, 48], ["the mitochondrial small subunit rRNA gene (mtSSU rRNA gene", "TREATMENT", 63, 121], ["nested PCR", "TEST", 154, 164], ["Pneumocystis", "OBSERVATION", 31, 43], ["small", "OBSERVATION_MODIFIER", 81, 86], ["subunit rRNA", "OBSERVATION", 87, 99]]], ["13 Cytological examination of the BAL fluid revealed a suppurative inflammation associated with the presence of intracellular coccobacilli bacteria.", [["BAL fluid", "ANATOMY", 34, 43], ["suppurative", "ANATOMY", 55, 66], ["intracellular", "ANATOMY", 112, 125], ["inflammation", "DISEASE", 67, 79], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 112, 125], ["Cytological examination", "TEST", 3, 26], ["the BAL fluid", "TEST", 30, 43], ["a suppurative inflammation", "PROBLEM", 53, 79], ["intracellular coccobacilli bacteria", "PROBLEM", 112, 147], ["BAL", "ANATOMY", 34, 37], ["suppurative", "OBSERVATION_MODIFIER", 55, 66], ["inflammation", "OBSERVATION", 67, 79], ["intracellular coccobacilli bacteria", "OBSERVATION", 112, 147]]], ["Urine culture and BAL fluid culture were positive for Escherichia coli (1,000,000 CFU) and Klebsiella pneumonia, respectively.", [["Urine culture", "ANATOMY", 0, 13], ["BAL fluid", "ANATOMY", 18, 27], ["Klebsiella pneumonia", "DISEASE", 91, 111], ["Urine", "ORGANISM_SUBSTANCE", 0, 5], ["BAL", "ORGANISM_SUBSTANCE", 18, 21], ["Escherichia coli", "ORGANISM", 54, 70], ["Escherichia coli", "SPECIES", 54, 70], ["Escherichia coli", "SPECIES", 54, 70], ["Klebsiella pneumonia", "SPECIES", 91, 111], ["Urine culture", "TEST", 0, 13], ["BAL fluid culture", "TEST", 18, 35], ["Escherichia coli", "PROBLEM", 54, 70], ["Klebsiella pneumonia", "PROBLEM", 91, 111], ["Escherichia coli", "OBSERVATION", 54, 70], ["Klebsiella", "OBSERVATION_MODIFIER", 91, 101], ["pneumonia", "OBSERVATION", 102, 111]]], ["Both microorganisms were sensitive to all antibiotic molecules tested on the antibiogram, and, surprisingly, included those used up to 4 days before presentation (i.e. amoxicillin-clavulanic acid).", [["amoxicillin-clavulanic acid", "CHEMICAL", 168, 195], ["amoxicillin-clavulanic acid", "CHEMICAL", 168, 195], ["amoxicillin-clavulanic acid", "SIMPLE_CHEMICAL", 168, 195], ["all antibiotic molecules", "TREATMENT", 38, 62], ["the antibiogram", "TEST", 73, 88], ["amoxicillin-clavulanic acid", "TREATMENT", 168, 195], ["microorganisms", "OBSERVATION", 5, 19]]], ["Polymerase chain reaction testing of BAL fluid was positive for B. bronchiseptica, Mycoplasma spp., and Pneumocystis spp.", [["BAL fluid", "ANATOMY", 37, 46], ["Mycoplasma spp.", "DISEASE", 83, 98], ["Pneumocystis spp", "DISEASE", 104, 120], ["BAL fluid", "ORGANISM_SUBSTANCE", 37, 46], ["B. bronchiseptica", "ORGANISM", 64, 81], ["Mycoplasma spp.", "ORGANISM", 83, 98], ["Pneumocystis spp", "ORGANISM", 104, 120], ["B. bronchiseptica", "SPECIES", 64, 81], ["Mycoplasma spp.", "SPECIES", 83, 98], ["Pneumocystis spp", "SPECIES", 104, 120], ["B. bronchiseptica", "SPECIES", 64, 81], ["Mycoplasma spp.", "SPECIES", 83, 98], ["Pneumocystis spp", "SPECIES", 104, 120], ["Polymerase chain reaction", "TEST", 0, 25], ["BAL fluid", "TEST", 37, 46], ["B. bronchiseptica", "PROBLEM", 64, 81], ["Mycoplasma spp.", "PROBLEM", 83, 98], ["Pneumocystis spp", "PROBLEM", 104, 120], ["BAL", "ANATOMY", 37, 40], ["Pneumocystis spp", "OBSERVATION", 104, 120]]], ["Pneumocystis identity was confirmed by sequencing of the mtSSU rRNA amplicon.", [["Pneumocystis", "DISEASE", 0, 12], ["Pneumocystis", "ORGANISM", 0, 12], ["mtSSU", "GENE_OR_GENE_PRODUCT", 57, 62], ["mtSSU rRNA amplicon", "DNA", 57, 76], ["Pneumocystis identity", "PROBLEM", 0, 21], ["the mtSSU rRNA amplicon", "TREATMENT", 53, 76]]], ["The unroot phylogenetic tree constructed using mtSSU rRNA sequences showed that Pneumocystis carinii f. sp. canis was distinct from Pneumocystis spp. isolated from other animals, confirming that this was the specific species related to canine hosts (Figure 3 ).", [["Pneumocystis carinii", "DISEASE", 80, 100], ["Pneumocystis spp", "DISEASE", 132, 148], ["Pneumocystis carinii", "ORGANISM", 80, 100], ["canis", "ORGANISM", 108, 113], ["Pneumocystis spp", "ORGANISM", 132, 148], ["canine", "ORGANISM", 236, 242], ["mtSSU rRNA sequences", "DNA", 47, 67], ["Pneumocystis carinii", "SPECIES", 80, 100], ["canis", "SPECIES", 108, 113], ["canine", "SPECIES", 236, 242], ["Pneumocystis carinii f. sp.", "SPECIES", 80, 107], ["canis", "SPECIES", 108, 113], ["Pneumocystis spp", "SPECIES", 132, 148], ["canine", "SPECIES", 236, 242], ["mtSSU rRNA sequences", "TEST", 47, 67], ["Pneumocystis carinii f.", "PROBLEM", 80, 103], ["canis", "PROBLEM", 108, 113], ["Pneumocystis spp", "PROBLEM", 132, 148], ["the specific species", "PROBLEM", 204, 224], ["Pneumocystis carinii", "OBSERVATION", 80, 100], ["distinct", "OBSERVATION_MODIFIER", 118, 126], ["Pneumocystis spp", "OBSERVATION", 132, 148]]], ["At the owner's request, at the end of all diagnostic procedures, the dog was discharged from the hospital, pending results and against medical advice.", [["dog", "ORGANISM", 69, 72], ["all diagnostic procedures", "TEST", 38, 63]]], ["At this time, the dog had fully recovered from the anesthesia and physical examination was unchanged compared to the morning admission.", [["dog", "ORGANISM", 18, 21], ["the anesthesia", "TREATMENT", 47, 61], ["physical examination", "TEST", 66, 86], ["unchanged", "OBSERVATION_MODIFIER", 91, 100]]], ["On the following morning, the dog returned in acute respiratory distress.", [["respiratory", "ANATOMY", 52, 63], ["respiratory distress", "DISEASE", 52, 72], ["dog", "ORGANISM", 30, 33], ["acute respiratory distress", "PROBLEM", 46, 72], ["acute", "OBSERVATION_MODIFIER", 46, 51], ["respiratory distress", "OBSERVATION", 52, 72]]], ["Thoracic radiographs showed a severe pneumothorax, and the animal died a short time later from cardiopulmonary arrest despite attempts to stabilize it.", [["pneumothorax", "DISEASE", 37, 49], ["cardiopulmonary arrest", "DISEASE", 95, 117], ["Thoracic radiographs", "TEST", 0, 20], ["a severe pneumothorax", "PROBLEM", 28, 49], ["cardiopulmonary arrest", "PROBLEM", 95, 117], ["severe", "OBSERVATION_MODIFIER", 30, 36], ["pneumothorax", "OBSERVATION", 37, 49], ["cardiopulmonary", "ANATOMY", 95, 110], ["arrest", "OBSERVATION", 111, 117]]], ["Post-mortem examination was declined from the owner.DiscussionThis case report, in the authors' opinion, highlights four points about the diagnosis and clinical presentation of dogs with Pneumocystis spp.", [["Pneumocystis spp", "DISEASE", 187, 203], ["dogs", "ORGANISM", 177, 181], ["dogs", "SPECIES", 177, 181], ["Post-mortem examination", "TEST", 0, 23], ["Pneumocystis spp", "PROBLEM", 187, 203], ["Pneumocystis spp", "OBSERVATION", 187, 203]]], ["First, in our laboratory, all reference intervals are calculated using a population of dogs matched for age, breed, and sex to the patient being tested.", [["dogs", "ORGANISM", 87, 91], ["patient", "ORGANISM", 131, 138], ["dogs", "SPECIES", 87, 91], ["patient", "SPECIES", 131, 138], ["a population of dogs", "TREATMENT", 71, 91]]], ["Dogs with chronic inflammatory disease (such as chronic septic pneumonia as in this case) often present with hypergammaglobulinemia and normal-to-high IgG concentration.", [["chronic inflammatory disease", "DISEASE", 10, 38], ["chronic septic pneumonia", "DISEASE", 48, 72], ["hypergammaglobulinemia", "DISEASE", 109, 131], ["Dogs", "ORGANISM", 0, 4], ["IgG", "GENE_OR_GENE_PRODUCT", 151, 154], ["IgG", "PROTEIN", 151, 154], ["chronic inflammatory disease", "PROBLEM", 10, 38], ["chronic septic pneumonia", "PROBLEM", 48, 72], ["hypergammaglobulinemia", "PROBLEM", 109, 131], ["chronic", "OBSERVATION_MODIFIER", 10, 17], ["inflammatory", "OBSERVATION", 18, 30], ["chronic", "OBSERVATION_MODIFIER", 48, 55], ["septic", "OBSERVATION_MODIFIER", 56, 62], ["pneumonia", "OBSERVATION", 63, 72], ["hypergammaglobulinemia", "OBSERVATION", 109, 131], ["normal", "OBSERVATION", 136, 142]]], ["14 The decreased gammaglobulins and IgG concentrations identified in this patient, together with the IgM and IgA in the lower limits of the reference intervals, were highly suspicious of an immunocompromised state, in agreement with previously reported cases of PP in CKCS.", [["CKCS", "DISEASE", 268, 272], ["gammaglobulins", "GENE_OR_GENE_PRODUCT", 17, 31], ["IgG", "GENE_OR_GENE_PRODUCT", 36, 39], ["patient", "ORGANISM", 74, 81], ["IgM", "GENE_OR_GENE_PRODUCT", 101, 104], ["IgA", "GENE_OR_GENE_PRODUCT", 109, 112], ["CKCS", "CANCER", 268, 272], ["gammaglobulins", "PROTEIN", 17, 31], ["IgG", "PROTEIN", 36, 39], ["IgM", "PROTEIN", 101, 104], ["IgA", "PROTEIN", 109, 112], ["patient", "SPECIES", 74, 81], ["The decreased gammaglobulins and IgG concentrations", "PROBLEM", 3, 54], ["the IgM", "TEST", 97, 104], ["IgA", "TEST", 109, 112], ["an immunocompromised state", "PROBLEM", 187, 213], ["PP in CKCS", "TREATMENT", 262, 272], ["decreased", "OBSERVATION_MODIFIER", 7, 16], ["IgG concentrations", "OBSERVATION_MODIFIER", 36, 54], ["lower limits", "OBSERVATION_MODIFIER", 120, 132], ["immunocompromised", "OBSERVATION", 190, 207]]], ["15, 16 Alternatively, the lack of vaccinations in this dog may has contributed to the low serum concentrations of gammaglobulins and IgG concentrations, 17 since reference intervals are derived from vaccinated animals.", [["serum", "ANATOMY", 90, 95], ["dog", "ORGANISM", 55, 58], ["serum", "ORGANISM_SUBSTANCE", 90, 95], ["gammaglobulins", "SIMPLE_CHEMICAL", 114, 128], ["IgG", "GENE_OR_GENE_PRODUCT", 133, 136], ["gammaglobulins", "PROTEIN", 114, 128], ["IgG", "PROTEIN", 133, 136], ["dog", "SPECIES", 55, 58], ["dog", "SPECIES", 55, 58], ["vaccinations", "TREATMENT", 34, 46], ["the low serum concentrations of gammaglobulins", "PROBLEM", 82, 128], ["IgG concentrations", "TEST", 133, 151]]], ["Second, the detection of the fungal pathogen was achieved through PCR testing of a BAL sample which was negative with microscopic visualization for Pneumocystis spp.", [["BAL sample", "ANATOMY", 83, 93], ["Pneumocystis spp", "DISEASE", 148, 164], ["the fungal pathogen", "PROBLEM", 25, 44], ["PCR testing", "TEST", 66, 77], ["a BAL sample", "TEST", 81, 93], ["microscopic visualization", "TEST", 118, 143], ["Pneumocystis spp", "PROBLEM", 148, 164], ["fungal pathogen", "OBSERVATION", 29, 44], ["Pneumocystis spp", "OBSERVATION", 148, 164]]], ["It must be considered that all Pneumocystis spp. have two developmental stages: the trophic form (formerly trophozoite) and the cyst form.", [["trophozoite", "ANATOMY", 107, 118], ["cyst", "ANATOMY", 128, 132], ["Pneumocystis spp", "DISEASE", 31, 47], ["Pneumocystis spp", "ORGANISM", 31, 47], ["all Pneumocystis spp", "PROBLEM", 27, 47], ["Pneumocystis", "OBSERVATION", 31, 43], ["developmental stages", "OBSERVATION_MODIFIER", 58, 78], ["trophic form", "OBSERVATION_MODIFIER", 84, 96], ["cyst", "OBSERVATION", 128, 132]]], ["The imbalance between the different lifecycle forms of Pneumocystis spp. might explain the lower diagnostic yield of cytology in certain instances, as cysts are much easier to distinguish than trophic forms using rapid, modified Romanowsky stains such as Diff-Quik.", [["cysts", "ANATOMY", 151, 156], ["Pneumocystis spp", "DISEASE", 55, 71], ["Pneumocystis spp", "ORGANISM", 55, 71], ["cysts", "PATHOLOGICAL_FORMATION", 151, 156], ["The imbalance", "PROBLEM", 0, 13], ["Pneumocystis spp", "PROBLEM", 55, 71], ["cytology", "TEST", 117, 125], ["cysts", "PROBLEM", 151, 156], ["modified Romanowsky stains", "TEST", 220, 246], ["Diff", "TEST", 255, 259], ["imbalance", "OBSERVATION", 4, 13], ["Pneumocystis spp", "OBSERVATION", 55, 71], ["cysts", "OBSERVATION", 151, 156]]], ["Such an explanation might account for why some specimens can be PCR-positive, yet no organisms can be detected using conventional light microscopy.", [["specimens", "ANATOMY", 47, 56], ["specimens", "CANCER", 47, 56], ["some specimens", "TEST", 42, 56], ["PCR", "TEST", 64, 67], ["organisms", "PROBLEM", 85, 94], ["conventional light microscopy", "TEST", 117, 146]]], ["2, 4, 6, 9 Similar to humans, PCR method to achieve a PP diagnosis has been suggested in dogs, 4,18 but it has only recently been used ante-mortem.", [["humans", "ORGANISM", 22, 28], ["dogs", "ORGANISM", 89, 93], ["humans", "SPECIES", 22, 28], ["dogs", "SPECIES", 89, 93], ["humans", "SPECIES", 22, 28], ["a PP diagnosis", "TEST", 52, 66]]], ["8, 9 These recent studies confirm that PCR testing can be a valid diagnostic test for the detection of Pneumocystis spp.", [["Pneumocystis spp", "DISEASE", 103, 119], ["Pneumocystis spp", "ORGANISM", 103, 119], ["Pneumocystis spp", "SPECIES", 103, 119], ["These recent studies", "TEST", 5, 25], ["PCR testing", "TEST", 39, 50], ["a valid diagnostic test", "TEST", 58, 81], ["Pneumocystis spp", "PROBLEM", 103, 119], ["Pneumocystis spp", "OBSERVATION", 103, 119]]], ["In addition, the phylogenetic analysis of the Pneumocystis spp. nucleic acid amplified from BAL fluid in the current study showed that it was a specific canine host-related species.DiscussionThe third peculiarity of this case report was the multiple bacteria identified by PCR and cultured from the BAL specimen and the presence of a concurrent urinary bacterial infection (i.e. E. coli).", [["BAL fluid", "ANATOMY", 92, 101], ["BAL specimen", "ANATOMY", 299, 311], ["urinary", "ANATOMY", 345, 352], ["Pneumocystis spp", "DISEASE", 46, 62], ["nucleic acid", "CHEMICAL", 64, 76], ["urinary bacterial infection", "DISEASE", 345, 372], ["Pneumocystis spp", "ORGANISM", 46, 62], ["BAL fluid", "ORGANISM_SUBSTANCE", 92, 101], ["canine", "ORGANISM", 153, 159], ["BAL specimen", "CANCER", 299, 311], ["E. coli", "ORGANISM", 379, 386], ["E. coli", "SPECIES", 379, 386], ["Pneumocystis spp", "SPECIES", 46, 62], ["canine", "SPECIES", 153, 159], ["E. coli", "SPECIES", 379, 386], ["the phylogenetic analysis", "TEST", 13, 38], ["the Pneumocystis spp", "PROBLEM", 42, 62], ["nucleic acid", "TEST", 64, 76], ["BAL fluid", "TEST", 92, 101], ["the current study", "TEST", 105, 122], ["a specific canine host-related species", "PROBLEM", 142, 180], ["the multiple bacteria", "PROBLEM", 237, 258], ["PCR", "TEST", 273, 276], ["the BAL specimen", "TEST", 295, 311], ["a concurrent urinary bacterial infection", "PROBLEM", 332, 372], ["E. coli", "PROBLEM", 379, 386], ["Pneumocystis spp", "OBSERVATION", 46, 62], ["acid", "OBSERVATION_MODIFIER", 72, 76], ["BAL fluid", "OBSERVATION", 92, 101], ["urinary", "ANATOMY", 345, 352], ["bacterial infection", "OBSERVATION", 353, 372], ["E. coli", "OBSERVATION", 379, 386]]], ["Although pulmonary co-infection with B. bronchiseptica has previously been reported, multiple coinfections with K. pneumonia, Mycoplasma spp., and Bordetella bronchiseptica, contemporary to a urinary tract infection with E. coli, have never been described before, further supporting the immune-suppression state of the dog.", [["pulmonary", "ANATOMY", 9, 18], ["urinary tract", "ANATOMY", 192, 205], ["pulmonary co-infection", "DISEASE", 9, 31], ["B. bronchiseptica", "DISEASE", 37, 54], ["coinfections", "DISEASE", 94, 106], ["K. pneumonia", "DISEASE", 112, 124], ["Mycoplasma spp.", "DISEASE", 126, 141], ["Bordetella bronchiseptica", "DISEASE", 147, 172], ["urinary tract infection", "DISEASE", 192, 215], ["pulmonary", "ORGAN", 9, 18], ["B. bronchiseptica", "ORGANISM", 37, 54], ["K. pneumonia", "ORGANISM", 112, 124], ["Mycoplasma spp.", "ORGANISM", 126, 141], ["Bordetella bronchiseptica", "ORGANISM", 147, 172], ["urinary tract", "ORGANISM", 192, 205], ["E. coli", "ORGANISM", 221, 228], ["dog", "ORGANISM", 319, 322], ["B. bronchiseptica", "SPECIES", 37, 54], ["K. pneumonia", "SPECIES", 112, 124], ["Mycoplasma spp.", "SPECIES", 126, 141], ["Bordetella bronchiseptica", "SPECIES", 147, 172], ["E. coli", "SPECIES", 221, 228], ["dog", "SPECIES", 319, 322], ["B. bronchiseptica", "SPECIES", 37, 54], ["K. pneumonia", "SPECIES", 112, 124], ["Mycoplasma spp.", "SPECIES", 126, 141], ["Bordetella bronchiseptica", "SPECIES", 147, 172], ["E. coli", "SPECIES", 221, 228], ["pulmonary co-infection", "PROBLEM", 9, 31], ["B. bronchiseptica", "PROBLEM", 37, 54], ["multiple coinfections", "PROBLEM", 85, 106], ["K. pneumonia", "PROBLEM", 112, 124], ["Mycoplasma spp.", "PROBLEM", 126, 141], ["Bordetella bronchiseptica", "PROBLEM", 147, 172], ["a urinary tract infection", "PROBLEM", 190, 215], ["E. coli", "PROBLEM", 221, 228], ["pulmonary", "ANATOMY", 9, 18], ["co-infection", "OBSERVATION", 19, 31], ["bronchiseptica", "OBSERVATION", 40, 54], ["multiple", "OBSERVATION_MODIFIER", 85, 93], ["coinfections", "OBSERVATION", 94, 106], ["pneumonia", "OBSERVATION", 115, 124], ["Mycoplasma spp.", "OBSERVATION", 126, 141], ["urinary tract", "ANATOMY", 192, 205], ["infection", "OBSERVATION", 206, 215], ["E. coli", "OBSERVATION", 221, 228]]], ["Moreover, it is also important to underline that all bacterial agents isolated by PCR and cultured are usually sensitive to one or more of the antimicrobial agents previously administered to the dog, supporting further the presence of an immunodeficient state in this patient.DiscussionThe final unusual finding of this report was that despite the detection of four different potential respiratory pathogens from the BAL sample, the lung changes in the thoracic radiographs were not especially severe, nor typical of PP.", [["BAL sample", "ANATOMY", 417, 427], ["lung", "ANATOMY", 433, 437], ["thoracic", "ANATOMY", 453, 461], ["dog", "ORGANISM", 195, 198], ["patient", "ORGANISM", 268, 275], ["BAL sample", "MULTI-TISSUE_STRUCTURE", 417, 427], ["lung", "ORGAN", 433, 437], ["thoracic", "ORGAN", 453, 461], ["patient", "SPECIES", 268, 275], ["all bacterial agents", "TREATMENT", 49, 69], ["PCR", "TEST", 82, 85], ["the antimicrobial agents", "TREATMENT", 139, 163], ["an immunodeficient state", "PROBLEM", 235, 259], ["four different potential respiratory pathogens", "PROBLEM", 361, 407], ["the BAL sample", "TEST", 413, 427], ["the lung changes", "PROBLEM", 429, 445], ["the thoracic radiographs", "TEST", 449, 473], ["PP", "PROBLEM", 517, 519], ["immunodeficient", "OBSERVATION", 238, 253], ["respiratory pathogens", "OBSERVATION", 386, 407], ["lung", "ANATOMY", 433, 437], ["thoracic", "ANATOMY", 453, 461]]], ["1,18 A possible explanation for this finding could be that the patient was in an initial stage of PP.", [["1,18", "CHEMICAL", 0, 4], ["patient", "ORGANISM", 63, 70], ["patient", "SPECIES", 63, 70], ["PP", "PROBLEM", 98, 100], ["possible explanation for", "UNCERTAINTY", 7, 31]]], ["Alternatively, it is possible that the Pneumocystis carinii f. sp. canis detected by PCR was just a colonizing respiratory tract of the dog without playing an active part in the pneumonia.", [["respiratory tract", "ANATOMY", 111, 128], ["Pneumocystis carinii", "DISEASE", 39, 59], ["canis", "DISEASE", 67, 72], ["pneumonia", "DISEASE", 178, 187], ["Pneumocystis carinii", "ORGANISM", 39, 59], ["f. sp", "ORGANISM", 60, 65], ["canis", "ORGANISM", 67, 72], ["respiratory tract", "ORGANISM_SUBDIVISION", 111, 128], ["dog", "ORGANISM", 136, 139], ["Pneumocystis carinii", "SPECIES", 39, 59], ["canis", "SPECIES", 67, 72], ["dog", "SPECIES", 136, 139], ["Pneumocystis carinii", "SPECIES", 39, 59], ["canis", "SPECIES", 67, 72], ["dog", "SPECIES", 136, 139], ["the Pneumocystis carinii f. sp", "PROBLEM", 35, 65], ["canis", "PROBLEM", 67, 72], ["the pneumonia", "PROBLEM", 174, 187], ["is possible", "UNCERTAINTY", 18, 29], ["Pneumocystis", "OBSERVATION_MODIFIER", 39, 51], ["carinii", "OBSERVATION", 52, 59], ["active", "OBSERVATION_MODIFIER", 159, 165], ["pneumonia", "OBSERVATION", 178, 187]]], ["Finally, the recent and multiple antibiotic treatments may have mitigated the intensity of the radiographic changes.DiscussionIn veterinary literature regarding PP, pneumothorax it has been reported only following a lung fine needle aspiration on a CKCS.", [["lung", "ANATOMY", 216, 220], ["pneumothorax", "DISEASE", 165, 177], ["CKCS", "DISEASE", 249, 253], ["lung", "ORGAN", 216, 220], ["multiple antibiotic treatments", "TREATMENT", 24, 54], ["the radiographic changes", "PROBLEM", 91, 115], ["PP", "PROBLEM", 161, 163], ["pneumothorax", "PROBLEM", 165, 177], ["a lung fine needle aspiration", "PROBLEM", 214, 243], ["a CKCS", "TREATMENT", 247, 253], ["pneumothorax", "OBSERVATION", 165, 177], ["lung", "ANATOMY", 216, 220], ["aspiration", "OBSERVATION", 233, 243]]], ["4 However, in human medicine, it is described as a clinical finding in 5%-10% of human patients affect by PP.", [["human", "ORGANISM", 14, 19], ["human", "ORGANISM", 81, 86], ["patients", "ORGANISM", 87, 95], ["human", "SPECIES", 14, 19], ["human", "SPECIES", 81, 86], ["patients", "SPECIES", 87, 95], ["human", "SPECIES", 14, 19], ["human", "SPECIES", 81, 86], ["PP", "TEST", 106, 108]]], ["19 Lung histology in these patients revealed a significant peripheral lung destruction characterized by sub-pleural necrosis and the presence of small and large sub-pleural cystic spaces.", [["Lung", "ANATOMY", 3, 7], ["lung", "ANATOMY", 70, 74], ["pleural", "ANATOMY", 108, 115], ["pleural cystic spaces", "ANATOMY", 165, 186], ["peripheral lung destruction", "DISEASE", 59, 86], ["sub-pleural necrosis", "DISEASE", 104, 124], ["Lung histology", "CANCER", 3, 17], ["patients", "ORGANISM", 27, 35], ["lung", "ORGAN", 70, 74], ["pleural", "PATHOLOGICAL_FORMATION", 108, 115], ["pleural cystic", "PATHOLOGICAL_FORMATION", 165, 179], ["patients", "SPECIES", 27, 35], ["Lung histology", "TEST", 3, 17], ["a significant peripheral lung destruction", "PROBLEM", 45, 86], ["sub-pleural necrosis", "PROBLEM", 104, 124], ["small and large sub-pleural cystic spaces", "PROBLEM", 145, 186], ["Lung", "ANATOMY", 3, 7], ["histology", "OBSERVATION", 8, 17], ["significant", "OBSERVATION_MODIFIER", 47, 58], ["peripheral", "ANATOMY_MODIFIER", 59, 69], ["lung", "ANATOMY", 70, 74], ["destruction", "OBSERVATION", 75, 86], ["sub", "OBSERVATION_MODIFIER", 104, 107], ["pleural", "ANATOMY", 108, 115], ["necrosis", "OBSERVATION", 116, 124], ["small", "OBSERVATION_MODIFIER", 145, 150], ["large", "OBSERVATION_MODIFIER", 155, 160], ["sub", "OBSERVATION_MODIFIER", 161, 164], ["pleural", "ANATOMY", 165, 172], ["cystic", "OBSERVATION", 173, 179]]], ["19 In this study, the patient's pneumothorax may have occurred secondary to airway endoscopy and BAL.", [["airway", "ANATOMY", 76, 82], ["pneumothorax", "DISEASE", 32, 44], ["patient", "ORGANISM", 22, 29], ["airway", "MULTI-TISSUE_STRUCTURE", 76, 82], ["patient", "SPECIES", 22, 29], ["this study", "TEST", 6, 16], ["the patient's pneumothorax", "PROBLEM", 18, 44], ["airway endoscopy", "TEST", 76, 92], ["BAL", "TEST", 97, 100], ["pneumothorax", "OBSERVATION", 32, 44], ["airway", "ANATOMY", 76, 82], ["endoscopy", "OBSERVATION", 83, 92]]], ["20 Finally, the lung damage caused by multiple infectious agents may also had played a role in the pathogenesis of the pneumothorax.", [["lung", "ANATOMY", 16, 20], ["lung damage", "DISEASE", 16, 27], ["pneumothorax", "DISEASE", 119, 131], ["lung", "ORGAN", 16, 20], ["the lung damage", "PROBLEM", 12, 27], ["multiple infectious agents", "TREATMENT", 38, 64], ["the pneumothorax", "PROBLEM", 115, 131], ["lung", "ANATOMY", 16, 20], ["damage", "OBSERVATION", 21, 27], ["multiple", "OBSERVATION_MODIFIER", 38, 46], ["infectious", "OBSERVATION", 47, 57], ["pneumothorax", "OBSERVATION", 119, 131]]], ["Unfortunately, at the owner's request and against medical advice, the dog was discharged from the hospital soon after the BAL procedure, preventing a watchful observation in an intensive care environment which may had altered the final outcome.DiscussionOne limitation of this case report is that we were not able to establish the fungal load and the pathological impact of Pneumocystis spp. on the respiratory signs of this dog.", [["BAL", "ANATOMY", 122, 125], ["respiratory", "ANATOMY", 399, 410], ["Pneumocystis spp", "DISEASE", 374, 390], ["dog", "ORGANISM", 70, 73], ["Pneumocystis", "ORGANISM", 374, 386], ["dog", "ORGANISM", 425, 428], ["dog", "SPECIES", 425, 428], ["the BAL procedure", "TREATMENT", 118, 135], ["a watchful observation", "TREATMENT", 148, 170], ["the fungal load", "PROBLEM", 327, 342], ["Pneumocystis spp", "PROBLEM", 374, 390], ["Pneumocystis spp", "OBSERVATION", 374, 390]]], ["Quantitative PCR assay to estimate the fungal load would have been useful for this purpose.", [["Quantitative PCR assay", "TEST", 0, 22], ["the fungal load", "TEST", 35, 50]]], ["9 Unfortunately, this technique was not available at the time of presentation of the dog reported here.ConclusionWhile signalment, medical history, clinicopathological, and nested PCR findings supported a PP diagnosis in our dog, the radiographic findings were not consistent with PP.", [["dog", "ORGANISM", 85, 88], ["dog", "ORGANISM", 225, 228], ["dog", "SPECIES", 225, 228], ["this technique", "TREATMENT", 17, 31], ["nested PCR findings", "TEST", 173, 192], ["the radiographic findings", "TEST", 230, 255], ["PP", "PROBLEM", 281, 283], ["not consistent with", "UNCERTAINTY", 261, 280]]], ["However, in human medicine, it is strongly recommended to consider the detection of Pneumocystis spp.", [["Pneumocystis spp", "DISEASE", 84, 100], ["human", "ORGANISM", 12, 17], ["Pneumocystis spp", "ORGANISM", 84, 100], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 12, 17], ["Pneumocystis spp", "SPECIES", 84, 100], ["Pneumocystis spp", "PROBLEM", 84, 100], ["Pneumocystis spp", "OBSERVATION", 84, 100]]], ["DNA in symptomatic patients, whatever the fungal load, to be at least partially, responsible for the clinical signs.", [["DNA", "CELLULAR_COMPONENT", 0, 3], ["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["DNA in symptomatic patients", "PROBLEM", 0, 27], ["the fungal load", "PROBLEM", 38, 53], ["the clinical signs", "TEST", 97, 115], ["symptomatic", "OBSERVATION_MODIFIER", 7, 18], ["fungal load", "OBSERVATION", 42, 53]]]], "PMC7309220": [["IntroductionWitnessing an alarmingly large number of novel pandemics in this century such as SARS, Swine Flue, MERS, Ebola, and Zika, there has been growing concerns on the \u201cnext big one\u201d [1].", [["SARS", "DISEASE", 93, 97], ["Ebola", "DISEASE", 117, 122], ["Zika", "DISEASE", 128, 132], ["SARS", "PROBLEM", 93, 97]]], ["Consequently, there are calls for technology-based preparedness [3], especially in the areas of infection prevention, case finding, case investigation, and contact tracing [4].", [["infection", "DISEASE", 96, 105], ["infection prevention", "TREATMENT", 96, 116], ["infection", "OBSERVATION", 96, 105]]], ["In this paper, we tackle one of the areas that need the technological revamping: contact tracing.IntroductionOn the brink of an infectious disease epidemic, the most urgent task is to trace those who possibly made contacts with the infected person(s), in order to cut the chain of infection and prevent it from growing into a wider epidemic.", [["infectious disease", "DISEASE", 128, 146], ["infection", "DISEASE", 281, 290], ["person", "SPECIES", 241, 247], ["contact tracing", "TEST", 81, 96], ["an infectious disease epidemic", "PROBLEM", 125, 155], ["infection", "PROBLEM", 281, 290], ["infectious", "OBSERVATION_MODIFIER", 128, 138], ["infection", "OBSERVATION", 281, 290]]], ["Meanwhile, recent outbreaks have been fundamentally different from those of the past \u2013 highly mobile populations [6] and the spread into densely populated cities [2] \u2013 which exacerbate the problem with the traditional contact tracing approach.IntroductionWhen there are many potential contacts that an infected person cannot identify or recollect as in our typical urban life, a potent tool we can marshal is the mobile devices such as smartphones.", [["person", "SPECIES", 311, 317], ["fundamentally", "OBSERVATION_MODIFIER", 38, 51], ["different", "OBSERVATION_MODIFIER", 52, 61]]], ["The mobile-based epidemic monitoring is nothing but a logical next step because only the mobile devices that move with people can keep up with the contacts they make.", [["people", "ORGANISM", 119, 125], ["people", "SPECIES", 119, 125], ["the mobile devices", "TREATMENT", 85, 103], ["mobile", "OBSERVATION_MODIFIER", 4, 10]]], ["Indeed, there have been increasing number of proposals for smartphone-based contact tracing.", [["increasing", "OBSERVATION_MODIFIER", 24, 34], ["number", "OBSERVATION_MODIFIER", 35, 41]]], ["The employed technologies range from similar Global Positioning System (GPS) positions [7], similar Wi-Fi fingerprints [8], Bluetooth peer discovery [9], and identical cells in mobile communication [10].", [["cells", "ANATOMY", 168, 173], ["cells", "CELL", 168, 173]]], ["Unfortunately, they either provide position information too coarse to be used for infectious contact detection [11] (GPS, cellular/Wi-Fi fingerprinting), require the infrastructure nearby (cellular/Wi-Fi), cannot be used indoors (GPS), consumes too much power for extended monitoring use (GPS) [12], or could compromise privacy by exposing the identity of the device and eventually its owner (Bluetooth beacons).IntroductionHowever, some recent works including our earlier pilot study [11], [13] present a new possibility by demonstrating that a magnetometer traces-based approach can detect close contacts.", [["cellular", "ANATOMY", 122, 130], ["cellular", "ANATOMY", 189, 197], ["cellular", "CELL", 122, 130], ["cellular", "CELL", 189, 197], ["infectious contact detection", "TEST", 82, 110], ["cellular/Wi-Fi fingerprinting", "TREATMENT", 122, 151], ["the device", "TREATMENT", 356, 366], ["our earlier pilot study", "TEST", 461, 484], ["a magnetometer traces", "TEST", 544, 565]]], ["They exploit the fact that the magnetic field strength is rich in spatial features (e.g. 1 m\u22121 to 0.01 m\u22121) [14] due to various distortions by ferromagnetic materials used in buildings such as reinforced concrete and metal doors.", [["various distortions", "PROBLEM", 120, 139], ["ferromagnetic materials", "TREATMENT", 143, 166], ["metal doors", "OBSERVATION", 217, 228]]], ["The magnetometer-based approach overcomes most of the aforementioned issues.", [["The magnetometer-based approach", "TREATMENT", 0, 31]]], ["Second, it offers better privacy protection by not revealing any identity of the device or the location of the trace generation.", [["the device", "TREATMENT", 77, 87], ["trace generation", "OBSERVATION", 111, 127]]], ["The low-power smartphone magnetometers can only be affected by ferromagnetic structures within a few meters [15], [16].", [["The low-power smartphone magnetometers", "TREATMENT", 0, 38], ["low", "OBSERVATION_MODIFIER", 4, 7]]], ["This last characteristics is especially important as many infectious disease transmissions occur in close distances.", [["many infectious disease transmissions", "PROBLEM", 53, 90], ["especially important", "UNCERTAINTY", 29, 49], ["infectious", "OBSERVATION_MODIFIER", 58, 68]]], ["Public health policies for tracing close contacts or infection control guidance often use a distance of up to 2 meters or 6 feet [18].IntroductionWhen the disease control authority performs an epidemiological investigation, they can use the smartphone magnetometer traces of the person confirmed infected and of the one suspected of a contact with the infected, in a system depicted in Fig. 1.", [["infection", "DISEASE", 53, 62], ["person", "SPECIES", 279, 285], ["infection control guidance", "TREATMENT", 53, 79], ["an epidemiological investigation", "TEST", 190, 222], ["disease", "OBSERVATION", 155, 162], ["infected", "OBSERVATION", 296, 304], ["infected", "OBSERVATION", 352, 360]]], ["When people make contacts, they are recorded in their individual phones in the form of similar magnetometer readings.", [["people", "ORGANISM", 5, 11], ["people", "SPECIES", 5, 11]]], ["When they want to check if they could have met an infected person, they can ask the system to compare their traces with that of the infected person.", [["person", "SPECIES", 59, 65], ["person", "SPECIES", 141, 147], ["infected", "OBSERVATION", 50, 58], ["infected", "OBSERVATION", 132, 140]]], ["Since it is a pairwise comparison, it works for the case many people gather at a location.", [["people", "ORGANISM", 62, 68], ["people", "SPECIES", 62, 68]]], ["In this paper, we assume that it is an emergency situation, and people are cooperating with the disease control authority by downloading an application that records the magnetometer readings and submits it through the phone\u2019s cellular connection if necessary.", [["cellular", "ANATOMY", 226, 234], ["people", "ORGANISM", 64, 70], ["cellular", "CELL", 226, 234], ["people", "SPECIES", 64, 70], ["the magnetometer readings", "TEST", 165, 190]]], ["In this effort by British Broadcasting Corporation (BBC), people are encouraged to download an app and activate it for helping model the spreading dynamics in future pandemics.", [["people", "ORGANISM", 58, 64], ["people", "SPECIES", 58, 64]]], ["Considering this precedent, our own system model in Fig. 1 is not excessively unrealistic.", [["not", "UNCERTAINTY", 62, 65], ["excessively", "OBSERVATION_MODIFIER", 66, 77], ["unrealistic", "OBSERVATION", 78, 89]]], ["Under the depicted scenario, not only the disease control authority but also each individual user can check herself whether or not there has been close contact with an infected person.", [["person", "SPECIES", 177, 183], ["infected", "OBSERVATION", 168, 176]]], ["Indeed, World Health Organization (WHO) strongly recommends that disease control authorities ensure at-risk populations have the information they need, thereby minimizing social and economic disruption [21].", [["disease control", "TREATMENT", 65, 80]]]], "dbef558c68d2b84710afbdba6f9fbc4efd51388d": [["In his eulogy for George Floyd, the Reverend Al Sharpton, stated, 'God took the rejected stone and made him the cornerstone of a movement that's going to change the whole wide world' (C-SPAN, 2020 ).", [["the rejected stone", "PROBLEM", 76, 94], ["stone", "OBSERVATION", 89, 94]]]]}